diseaseid	CellDeathType	Disease	pmid	Description
8	anoikis	acute myelogenous leukemia	12897778	Studies of two AML cell lines, U937 and HL60, which express the β1 integrins VLA4 and VLA5, showed that they were more resistant to loss-of-anchorage induced apoptosis (anoikis) after treatment with the anticancer drugs daunorubicin and AraC if attached to fibronectin-coated plates than those incubated on plates with no fibronectin coating. 
9	anoikis	aneurysms and varicose veins	14551156	Anoïkis is probably involved in pathological remodeling of cardiovascular tissues, including cardiac myocyte detachment in heart failure, deendothelialization and plaque rupture in atherosclerosis, and smooth muscle cell disappearance in aneurysms and varicose veins. 
10	anoikis	atherosclerosis	14551156	Anoïkis is probably involved in pathological remodeling of cardiovascular tissues, including cardiac myocyte detachment in heart failure, deendothelialization and plaque rupture in atherosclerosis, and smooth muscle cell disappearance in aneurysms and varicose veins. 
11	anoikis	Cardiovascular degenerative pathologies	18708031	Disease states associated with a pathophysiological induction of anoikis.
12	anoikis	cardiovascular diseases	21953325	The aim of this review is to analyse the molecular mechanisms governing both anoikis and anoikis resistance, focusing on their regulation in physiological processes, as well as in several diseases, including metastatic cancers, cardiovascular diseases and diabetes. 
13	anoikis	diabetes	21953325	The aim of this review is to analyse the molecular mechanisms governing both anoikis and anoikis resistance, focusing on their regulation in physiological processes, as well as in several diseases, including metastatic cancers, cardiovascular diseases and diabetes. 
14	anoikis	diabetic foot	38468369	Previous research has shown a correlation between diabetic foot ulcers, neuropathy, vasculopathy, increased endothelial cell detachment and premature death caused by anoikis.8 Hence, anoikis may play a crucial role in the occurrence and progression of diabetic foot.
15	anoikis	Ethanol-induced central nervous system dysfunctions	18708031	Disease states associated with a pathophysiological induction of anoikis.
16	anoikis	heart failure	14551156	Anoïkis is probably involved in pathological remodeling of cardiovascular tissues, including cardiac myocyte detachment in heart failure, deendothelialization and plaque rupture in atherosclerosis, and smooth muscle cell disappearance in aneurysms and varicose veins. 
17	anoikis	Osteoarthritis (OA) 	38423139	Osteoarthritis (OA) is a degenerative disease closely associated with Anoikis.
18	anoikis	Renal glomerular disease	18708031	Disease states associated with a pathophysiological induction of anoikis.
19	anoikis	rheumatoid arthritis (RA).	38046810	Anoikis-related genes were highly correlated with HLA genes.
20	anoikis	Vascular dysfunction in diabetes	18708031	Disease states associated with a pathophysiological induction of anoikis.
id	Symbol	Type	hgncid	name	locus_type	status	entrez_id	ensembl_gene_id	uniprot_ids
11171	ANKRD13C	anoikis	HGNC:25374	ankyrin repeat domain 13C	gene with protein product	Approved	81573	ENSG00000118454	Q8N6S4
11172	BCL2	anoikis	HGNC:990	BCL2 apoptosis regulator	gene with protein product	Approved	596	ENSG00000171791	P10415
11173	BCL2L1	anoikis	HGNC:992	BCL2 like 1	gene with protein product	Approved	598	ENSG00000171552	Q07817
11174	BMF	anoikis	HGNC:24132	Bcl2 modifying factor	gene with protein product	Approved	90427	ENSG00000104081	Q96LC9
11175	BRMS1	anoikis	HGNC:17262	BRMS1 transcriptional repressor and anoikis regulator	gene with protein product	Approved	25855	ENSG00000174744	Q9HCU9
11176	CAV1	anoikis	HGNC:1527	caveolin 1	gene with protein product	Approved	857	ENSG00000105974	Q03135
11177	CHEK2	anoikis	HGNC:16627	checkpoint kinase 2	gene with protein product	Approved	11200	ENSG00000183765	O96017
11178	CRYBA1	anoikis	HGNC:2394	crystallin beta A1	gene with protein product	Approved	1411	ENSG00000108255	P05813
11179	DAPK2	anoikis	HGNC:2675	death associated protein kinase 2	gene with protein product	Approved	23604	ENSG00000035664	Q9UIK4
11180	E2F1	anoikis	HGNC:3113	E2F transcription factor 1	gene with protein product	Approved	1869	ENSG00000101412	Q01094
11181	IKBKG	anoikis	HGNC:5961	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	gene with protein product	Approved	8517	ENSG00000269335	Q9Y6K9
11182	ITGA5	anoikis	HGNC:6141	integrin subunit alpha 5	gene with protein product	Approved	3678	ENSG00000161638	P08648
11183	ITGB1	anoikis	HGNC:6153	integrin subunit beta 1	gene with protein product	Approved	3688	ENSG00000150093	P05556
11184	MAP3K7	anoikis	HGNC:6859	mitogen-activated protein kinase kinase kinase 7	gene with protein product	Approved	6885	ENSG00000135341	O43318
11185	MCL1	anoikis	HGNC:6943	MCL1 apoptosis regulator, BCL2 family member	gene with protein product	Approved	4170	ENSG00000143384	Q07820
11186	MYBBP1A	anoikis	HGNC:7546	MYB binding protein 1a	gene with protein product	Approved	10514	ENSG00000132382	Q9BQG0
11187	NOTCH1	anoikis	HGNC:7881	notch receptor 1	gene with protein product	Approved	4851	ENSG00000148400	P46531
11188	NTRK2	anoikis	HGNC:8032	neurotrophic receptor tyrosine kinase 2	gene with protein product	Approved	4915	ENSG00000148053	Q16620
11189	PDK4	anoikis	HGNC:8812	pyruvate dehydrogenase kinase 4	gene with protein product	Approved	5166	ENSG00000004799	Q16654
11190	PIK3CA	anoikis	HGNC:8975	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	gene with protein product	Approved	5290	ENSG00000121879	P42336
11191	PTK2	anoikis	HGNC:9611	protein tyrosine kinase 2	gene with protein product	Approved	5747	ENSG00000169398	Q05397
11192	PTRH2	anoikis	HGNC:24265	peptidyl-tRNA hydrolase 2	gene with protein product	Approved	51651	ENSG00000141378	Q9Y3E5
11193	SIK1	anoikis	HGNC:11142	salt inducible kinase 1	gene with protein product	Approved	150094	ENSG00000142178	P57059
11194	SNAI2	anoikis	HGNC:11094	snail family transcriptional repressor 2	gene with protein product	Approved	6591	ENSG00000019549	O43623
11195	SRC	anoikis	HGNC:11283	SRC proto-oncogene, non-receptor tyrosine kinase	gene with protein product	Approved	6714	ENSG00000197122	P12931
11196	STK11	anoikis	HGNC:11389	serine/threonine kinase 11	gene with protein product	Approved	6794	ENSG00000118046	Q15831
11197	TFDP1	anoikis	HGNC:11749	transcription factor Dp-1	gene with protein product	Approved	7027	ENSG00000198176	Q14186
11198	TLE1	anoikis	HGNC:11837	TLE family member 1, transcriptional corepressor	gene with protein product	Approved	7088	ENSG00000196781	Q04724
11199	TSC2	anoikis	HGNC:12363	TSC complex subunit 2	gene with protein product	Approved	7249	ENSG00000103197	P49815
lncid	cdtype	lncRNA	lnctarget	pmid	description
128860	anoikis	MIR31HG	ANKRD13C	24297251	starBase v2.0
128861	anoikis	HHLA3	ANKRD13C	24297251	starBase v2.0
128862	anoikis	AL592166.1	ANKRD13C	24297251	starBase v2.0
128863	anoikis	ZRANB2-AS2	ANKRD13C	24297251	starBase v2.0
128864	anoikis	Z93403.1	ANKRD13C	24297251	starBase v2.0
128865	anoikis	LINC01135	ANKRD13C	24297251	starBase v2.0
128866	anoikis	LINC01135	ANKRD13C	24297251	starBase v2.0
128867	anoikis	AP001574.1	ANKRD13C	24297251	starBase v2.0
128868	anoikis	CASC19	ANKRD13C	24297251	starBase v2.0
128869	anoikis	LOXL1-AS1	ANKRD13C	24297251	starBase v2.0
128870	anoikis	NIPBL-DT	ANKRD13C	24297251	starBase v2.0
128871	anoikis	FAM153CP	ANKRD13C	24297251	starBase v2.0
128872	anoikis	NEAT1	ANKRD13C	24297251	starBase v2.0
128873	anoikis	NEAT1	ANKRD13C	24297251	starBase v2.0
128874	anoikis	AC093866.1	ANKRD13C	24297251	starBase v2.0
128875	anoikis	MALAT1	ANKRD13C	24297251	starBase v2.0
128876	anoikis	MALAT1	ANKRD13C	24297251	starBase v2.0
128877	anoikis	MALAT1	ANKRD13C	24297251	starBase v2.0
128878	anoikis	MALAT1	ANKRD13C	24297251	starBase v2.0
128879	anoikis	MALAT1	ANKRD13C	24297251	starBase v2.0
128880	anoikis	MALAT1	ANKRD13C	24297251	starBase v2.0
128881	anoikis	MALAT1	ANKRD13C	24297251	starBase v2.0
128882	anoikis	LINC01579	ANKRD13C	24297251	starBase v2.0
128883	anoikis	PARD6G-AS1	ANKRD13C	24297251	starBase v2.0
128884	anoikis	DNAH17-AS1	ANKRD13C	24297251	starBase v2.0
128885	anoikis	NUTM2B-AS1	BCL2	24297251	starBase v2.0
128886	anoikis	LINC01278	BCL2	24297251	starBase v2.0
128887	anoikis	LINC00894	BCL2	24297251	starBase v2.0
128888	anoikis	AL603839.3	BCL2	24297251	starBase v2.0
128889	anoikis	SNHG3	BCL2	24297251	starBase v2.0
128890	anoikis	PVT1	BCL2	24297251	starBase v2.0
128891	anoikis	LINC02732	BCL2	24297251	starBase v2.0
128892	anoikis	AC130895.1	BCL2	24297251	starBase v2.0
128893	anoikis	CYTOR	BCL2	24297251	starBase v2.0
128894	anoikis	NUP50-DT	BCL2	24297251	starBase v2.0
128895	anoikis	FTX	BCL2	24297251	starBase v2.0
128896	anoikis	TRAF3IP2-AS1	BCL2	24297251	starBase v2.0
128897	anoikis	ZNF529-AS1	BCL2	24297251	starBase v2.0
128898	anoikis	SNHG6	BCL2	24297251	starBase v2.0
128899	anoikis	MALAT1	BCL2	24297251	starBase v2.0
128900	anoikis	MALAT1	BCL2	24297251	starBase v2.0
128901	anoikis	MALAT1	BCL2	24297251	starBase v2.0
128902	anoikis	MALAT1	BCL2	24297251	starBase v2.0
128903	anoikis	MALAT1	BCL2	24297251	starBase v2.0
128904	anoikis	CASC19	BCL2	24297251	starBase v2.0
128905	anoikis	CASC19	BCL2	24297251	starBase v2.0
128906	anoikis	AC004687.1	BCL2	24297251	starBase v2.0
128907	anoikis	HEIH	BCL2	24297251	starBase v2.0
128908	anoikis	MDS2	BCL2L1	24297251	starBase v2.0
128909	anoikis	FAM153CP	BCL2L1	24297251	starBase v2.0
128910	anoikis	AC131097.2	BCL2L1	24297251	starBase v2.0
128911	anoikis	HM13-IT1	BCL2L1	24297251	starBase v2.0
128912	anoikis	MALAT1	BCL2L1	24297251	starBase v2.0
128913	anoikis	MALAT1	BCL2L1	24297251	starBase v2.0
128914	anoikis	MALAT1	BCL2L1	24297251	starBase v2.0
128915	anoikis	MALAT1	BCL2L1	24297251	starBase v2.0
128916	anoikis	MALAT1	BCL2L1	24297251	starBase v2.0
128917	anoikis	MALAT1	BCL2L1	24297251	starBase v2.0
128918	anoikis	MALAT1	BCL2L1	24297251	starBase v2.0
128919	anoikis	MALAT1	BCL2L1	24297251	starBase v2.0
128920	anoikis	AL139023.1	BCL2L1	24297251	starBase v2.0
128921	anoikis	AL358334.2	BCL2L1	24297251	starBase v2.0
128922	anoikis	LINC01355	BCL2L1	24297251	starBase v2.0
128923	anoikis	SNHG29	BCL2L1	24297251	starBase v2.0
128924	anoikis	PAX8-AS1	BCL2L1	24297251	starBase v2.0
128925	anoikis	AC093904.2	BCL2L1	24297251	starBase v2.0
128926	anoikis	NEAT1	BCL2L1	24297251	starBase v2.0
128927	anoikis	NEAT1	BCL2L1	24297251	starBase v2.0
128928	anoikis	NEAT1	BCL2L1	24297251	starBase v2.0
128929	anoikis	CASC19	BCL2L1	24297251	starBase v2.0
128930	anoikis	LINC02307	BCL2L1	24297251	starBase v2.0
128931	anoikis	PVT1	BRMS1	24297251	starBase v2.0
128932	anoikis	AC116351.1	BRMS1	24297251	starBase v2.0
128933	anoikis	ST7-OT4	CAV1	24297251	starBase v2.0
128934	anoikis	NEAT1	CAV1	24297251	starBase v2.0
128935	anoikis	MALAT1	CAV1	24297251	starBase v2.0
128936	anoikis	MALAT1	CAV1	24297251	starBase v2.0
128937	anoikis	MALAT1	CAV1	24297251	starBase v2.0
128938	anoikis	AL357172.1	CAV1	24297251	starBase v2.0
128939	anoikis	NORAD	CAV1	24297251	starBase v2.0
128940	anoikis	NORAD	CAV1	24297251	starBase v2.0
128941	anoikis	LINC01090	CAV1	24297251	starBase v2.0
128942	anoikis	LINC02043	CAV1	24297251	starBase v2.0
128943	anoikis	SNHG1	CAV1	24297251	starBase v2.0
128944	anoikis	MALAT1	CHEK2	24297251	starBase v2.0
128945	anoikis	MALAT1	CHEK2	24297251	starBase v2.0
128946	anoikis	MIR100HG	CHEK2	24297251	starBase v2.0
128947	anoikis	ENTPD1-AS1	CHEK2	24297251	starBase v2.0
128948	anoikis	SNHG3	CHEK2	24297251	starBase v2.0
128949	anoikis	FGF14-IT1	CHEK2	24297251	starBase v2.0
128950	anoikis	PVT1	CHEK2	24297251	starBase v2.0
128951	anoikis	BMS1P4	CHEK2	24297251	starBase v2.0
128952	anoikis	HELLPAR	CHEK2	24297251	starBase v2.0
128953	anoikis	GATA2-AS1	DAPK2	24297251	starBase v2.0
128954	anoikis	MALAT1	DAPK2	24297251	starBase v2.0
128955	anoikis	MALAT1	DAPK2	24297251	starBase v2.0
128956	anoikis	USP3-AS1	DAPK2	24297251	starBase v2.0
128957	anoikis	LINC02137	DAPK2	24297251	starBase v2.0
128958	anoikis	LINC02861	DAPK2	24297251	starBase v2.0
128959	anoikis	AC011444.1	DAPK2	24297251	starBase v2.0
128960	anoikis	MIR31HG	DAPK2	24297251	starBase v2.0
128961	anoikis	RAB30-DT	DAPK2	24297251	starBase v2.0
128962	anoikis	AC242022.2	DAPK2	24297251	starBase v2.0
128963	anoikis	FTX	E2F1	24297251	starBase v2.0
128964	anoikis	AC134349.1	E2F1	24297251	starBase v2.0
128965	anoikis	MIRLET7BHG	E2F1	24297251	starBase v2.0
128966	anoikis	AL606491.1	E2F1	24297251	starBase v2.0
128967	anoikis	NUP50-DT	E2F1	24297251	starBase v2.0
128968	anoikis	DLEU2	E2F1	24297251	starBase v2.0
128969	anoikis	MALAT1	E2F1	24297251	starBase v2.0
128970	anoikis	MALAT1	E2F1	24297251	starBase v2.0
128971	anoikis	FIRRE	IKBKG	24297251	starBase v2.0
128972	anoikis	UBA6-AS1	IKBKG	24297251	starBase v2.0
128973	anoikis	AC011603.2	IKBKG	24297251	starBase v2.0
128974	anoikis	LINC01886	IKBKG	24297251	starBase v2.0
128975	anoikis	MALAT1	IKBKG	24297251	starBase v2.0
128976	anoikis	AC008770.3	IKBKG	24297251	starBase v2.0
128977	anoikis	MIR924HG	IKBKG	24297251	starBase v2.0
128978	anoikis	AL117379.1	IKBKG	24297251	starBase v2.0
128979	anoikis	AL049557.1	IKBKG	24297251	starBase v2.0
128980	anoikis	MSC-AS1	ITGA5	24297251	starBase v2.0
128981	anoikis	NEAT1	ITGA5	24297251	starBase v2.0
128982	anoikis	NEAT1	ITGA5	24297251	starBase v2.0
128983	anoikis	CASC19	ITGA5	24297251	starBase v2.0
128984	anoikis	LINC02693	ITGA5	24297251	starBase v2.0
128985	anoikis	POLR2J4	ITGA5	24297251	starBase v2.0
128986	anoikis	MCM3AP-AS1	ITGA5	24297251	starBase v2.0
128987	anoikis	AL355574.1	ITGA5	24297251	starBase v2.0
128988	anoikis	MALAT1	ITGA5	24297251	starBase v2.0
128989	anoikis	AC016831.6	ITGA5	24297251	starBase v2.0
128990	anoikis	BX890604.1	ITGA5	24297251	starBase v2.0
128991	anoikis	DLEU1	ITGB1	24297251	starBase v2.0
128992	anoikis	AC016747.1	ITGB1	24297251	starBase v2.0
128993	anoikis	AC242426.2	ITGB1	24297251	starBase v2.0
128994	anoikis	AC084816.1	ITGB1	24297251	starBase v2.0
128995	anoikis	AL117336.2	ITGB1	24297251	starBase v2.0
128996	anoikis	EBLN3P	ITGB1	24297251	starBase v2.0
128997	anoikis	MIR99AHG	ITGB1	24297251	starBase v2.0
128998	anoikis	MIR646HG	ITGB1	24297251	starBase v2.0
128999	anoikis	SNHG31	ITGB1	24297251	starBase v2.0
129000	anoikis	FTX	ITGB1	24297251	starBase v2.0
129001	anoikis	FTX	ITGB1	24297251	starBase v2.0
129002	anoikis	MMADHC-DT	ITGB1	24297251	starBase v2.0
129003	anoikis	GAS5	ITGB1	24297251	starBase v2.0
129004	anoikis	NEAT1	ITGB1	24297251	starBase v2.0
129005	anoikis	NEAT1	ITGB1	24297251	starBase v2.0
129006	anoikis	AC024230.1	ITGB1	24297251	starBase v2.0
129007	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129008	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129009	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129010	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129011	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129012	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129013	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129014	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129015	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129016	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129017	anoikis	MALAT1	ITGB1	24297251	starBase v2.0
129018	anoikis	PCAT1	ITGB1	24297251	starBase v2.0
129019	anoikis	OTUD6B-AS1	ITGB1	24297251	starBase v2.0
129020	anoikis	CASC19	ITGB1	24297251	starBase v2.0
129021	anoikis	CASC19	ITGB1	24297251	starBase v2.0
129022	anoikis	CASC19	ITGB1	24297251	starBase v2.0
129023	anoikis	AC113414.1	ITGB1	24297251	starBase v2.0
129024	anoikis	AL358334.2	ITGB1	24297251	starBase v2.0
129025	anoikis	AC022167.2	ITGB1	24297251	starBase v2.0
129026	anoikis	AC021087.3	ITGB1	24297251	starBase v2.0
129027	anoikis	ZNF213-AS1	ITGB1	24297251	starBase v2.0
129028	anoikis	FENDRR	ITGB1	24297251	starBase v2.0
129029	anoikis	NEAT1	MAP3K7	24297251	starBase v2.0
129030	anoikis	MALAT1	MAP3K7	24297251	starBase v2.0
129031	anoikis	MALAT1	MAP3K7	24297251	starBase v2.0
129032	anoikis	MALAT1	MAP3K7	24297251	starBase v2.0
129033	anoikis	JRKL-AS1	MAP3K7	24297251	starBase v2.0
129034	anoikis	AC087762.1	MAP3K7	24297251	starBase v2.0
129035	anoikis	AL033504.1	MAP3K7	24297251	starBase v2.0
129036	anoikis	C5orf17	MAP3K7	24297251	starBase v2.0
129037	anoikis	AC005355.1	MAP3K7	24297251	starBase v2.0
129038	anoikis	NORAD	MAP3K7	24297251	starBase v2.0
129039	anoikis	AC018647.2	MAP3K7	24297251	starBase v2.0
129040	anoikis	THUMPD3-AS1	MCL1	24297251	starBase v2.0
129041	anoikis	POLR2J4	MCL1	24297251	starBase v2.0
129042	anoikis	MEIS1-AS3	MCL1	24297251	starBase v2.0
129043	anoikis	HOTAIRM1	MCL1	24297251	starBase v2.0
129044	anoikis	NEAT1	MCL1	24297251	starBase v2.0
129045	anoikis	CASC19	MCL1	24297251	starBase v2.0
129046	anoikis	RNF216P1	MCL1	24297251	starBase v2.0
129047	anoikis	LINC02471	MCL1	24297251	starBase v2.0
129048	anoikis	MIR181A2HG	MCL1	24297251	starBase v2.0
129049	anoikis	AL589935.1	MCL1	24297251	starBase v2.0
129050	anoikis	AL117378.1	MCL1	24297251	starBase v2.0
129051	anoikis	AP000662.1	MCL1	24297251	starBase v2.0
129052	anoikis	RASSF10-DT	MCL1	24297251	starBase v2.0
129053	anoikis	AL357153.2	MCL1	24297251	starBase v2.0
129054	anoikis	AL049828.1	MCL1	24297251	starBase v2.0
129055	anoikis	AC234031.1	MCL1	24297251	starBase v2.0
129056	anoikis	NEAT1	NOTCH1	24297251	starBase v2.0
129057	anoikis	NEAT1	NOTCH1	24297251	starBase v2.0
129058	anoikis	NEAT1	NOTCH1	24297251	starBase v2.0
129059	anoikis	PVT1	NOTCH1	24297251	starBase v2.0
129060	anoikis	AP003559.1	NOTCH1	24297251	starBase v2.0
129061	anoikis	LINC01572	NOTCH1	24297251	starBase v2.0
129062	anoikis	FENDRR	NOTCH1	24297251	starBase v2.0
129063	anoikis	N4BP2L2-IT2	NOTCH1	24297251	starBase v2.0
129064	anoikis	MALAT1	PDK4	24297251	starBase v2.0
129065	anoikis	MIR100HG	PDK4	24297251	starBase v2.0
129066	anoikis	AL139220.2	PDK4	24297251	starBase v2.0
129067	anoikis	NEAT1	PDK4	24297251	starBase v2.0
129068	anoikis	NEAT1	PDK4	24297251	starBase v2.0
129069	anoikis	LINC00457	PIK3CA	24297251	starBase v2.0
129070	anoikis	MIR4500HG	PIK3CA	24297251	starBase v2.0
129071	anoikis	MIR100HG	PIK3CA	24297251	starBase v2.0
129072	anoikis	AL121694.1	PIK3CA	24297251	starBase v2.0
129073	anoikis	MIR924HG	PIK3CA	24297251	starBase v2.0
129074	anoikis	NUTM2B-AS1	PIK3CA	24297251	starBase v2.0
129075	anoikis	NUTM2B-AS1	PIK3CA	24297251	starBase v2.0
129076	anoikis	NEAT1	PIK3CA	24297251	starBase v2.0
129077	anoikis	NEAT1	PIK3CA	24297251	starBase v2.0
129078	anoikis	NEAT1	PIK3CA	24297251	starBase v2.0
129079	anoikis	MALAT1	PIK3CA	24297251	starBase v2.0
129080	anoikis	MALAT1	PIK3CA	24297251	starBase v2.0
129081	anoikis	AC091132.4	PIK3CA	24297251	starBase v2.0
129082	anoikis	SNHG16	PTK2	24297251	starBase v2.0
129083	anoikis	AC069277.1	PTK2	24297251	starBase v2.0
129084	anoikis	MIRLET7BHG	PTK2	24297251	starBase v2.0
129085	anoikis	MIRLET7BHG	PTK2	24297251	starBase v2.0
129086	anoikis	NBR2	PTK2	24297251	starBase v2.0
129087	anoikis	AP000812.1	PTK2	24297251	starBase v2.0
129088	anoikis	MIR99AHG	PTK2	24297251	starBase v2.0
129089	anoikis	ARHGAP27P1-BPTFP1-KPNA2P3	PTK2	24297251	starBase v2.0
129090	anoikis	ASTN2-AS1	PTK2	24297251	starBase v2.0
129091	anoikis	AJ009632.2	PTK2	24297251	starBase v2.0
129092	anoikis	FTX	PTK2	24297251	starBase v2.0
129093	anoikis	FTX	PTK2	24297251	starBase v2.0
129094	anoikis	FTX	PTK2	24297251	starBase v2.0
129095	anoikis	FTX	PTK2	24297251	starBase v2.0
129096	anoikis	LINC01273	PTK2	24297251	starBase v2.0
129097	anoikis	LINC00472	PTK2	24297251	starBase v2.0
129098	anoikis	AC019186.1	PTK2	24297251	starBase v2.0
129099	anoikis	AL138799.3	PTK2	24297251	starBase v2.0
129100	anoikis	NIFK-AS1	PTK2	24297251	starBase v2.0
129101	anoikis	ZEB1-AS1	PTK2	24297251	starBase v2.0
129102	anoikis	AL365295.1	PTK2	24297251	starBase v2.0
129103	anoikis	SNHG3	PTK2	24297251	starBase v2.0
129104	anoikis	AC092910.3	PTK2	24297251	starBase v2.0
129105	anoikis	LINC01184	PTK2	24297251	starBase v2.0
129106	anoikis	RAB30-DT	PTK2	24297251	starBase v2.0
129107	anoikis	LY6E-DT	PTK2	24297251	starBase v2.0
129108	anoikis	OIP5-AS1	PTK2	24297251	starBase v2.0
129109	anoikis	AC010307.2	PTK2	24297251	starBase v2.0
129110	anoikis	AC005920.2	PTK2	24297251	starBase v2.0
129111	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129112	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129113	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129114	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129115	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129116	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129117	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129118	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129119	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129120	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129121	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129122	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129123	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129124	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129125	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129126	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129127	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129128	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129129	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129130	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129131	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129132	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129133	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129134	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129135	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129136	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129137	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129138	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129139	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129140	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129141	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129142	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129143	anoikis	MALAT1	PTK2	24297251	starBase v2.0
129144	anoikis	PCAT1	PTK2	24297251	starBase v2.0
129145	anoikis	AL049629.1	PTK2	24297251	starBase v2.0
129146	anoikis	AL359232.1	PTK2	24297251	starBase v2.0
129147	anoikis	AC107375.1	PTK2	24297251	starBase v2.0
129148	anoikis	MIR924HG	PTK2	24297251	starBase v2.0
129149	anoikis	MIR924HG	PTK2	24297251	starBase v2.0
129150	anoikis	DNAH17-AS1	PTK2	24297251	starBase v2.0
129151	anoikis	AC008750.4	PTK2	24297251	starBase v2.0
129152	anoikis	AC008035.1	PTK2	24297251	starBase v2.0
129153	anoikis	SYNGAP1-AS1	PTK2	24297251	starBase v2.0
129154	anoikis	AC026368.1	PTK2	24297251	starBase v2.0
129155	anoikis	AL021368.4	PTK2	24297251	starBase v2.0
129156	anoikis	LINC00842	PTK2	24297251	starBase v2.0
129157	anoikis	AL160254.1	PTK2	24297251	starBase v2.0
129158	anoikis	AP001977.1	PTK2	24297251	starBase v2.0
129159	anoikis	MIR31HG	PTK2	24297251	starBase v2.0
129160	anoikis	MIR31HG	PTK2	24297251	starBase v2.0
129161	anoikis	ZNF337-AS1	PTK2	24297251	starBase v2.0
129162	anoikis	CYTOR	PTK2	24297251	starBase v2.0
129163	anoikis	AL049569.1	PTK2	24297251	starBase v2.0
129164	anoikis	AL357793.1	PTK2	24297251	starBase v2.0
129165	anoikis	SLC2A1-AS1	PTK2	24297251	starBase v2.0
129166	anoikis	AL160408.1	PTK2	24297251	starBase v2.0
129167	anoikis	AC021078.1	PTK2	24297251	starBase v2.0
129168	anoikis	AC093423.2	PTK2	24297251	starBase v2.0
129169	anoikis	DLEU2	PTK2	24297251	starBase v2.0
129170	anoikis	AL365436.2	PTK2	24297251	starBase v2.0
129171	anoikis	AL365436.2	PTK2	24297251	starBase v2.0
129172	anoikis	AC019068.1	PTK2	24297251	starBase v2.0
129173	anoikis	AC073529.1	PTK2	24297251	starBase v2.0
129174	anoikis	AF127577.4	PTK2	24297251	starBase v2.0
129175	anoikis	AC068759.1	PTK2	24297251	starBase v2.0
129176	anoikis	ZBTB20-AS5	PTK2	24297251	starBase v2.0
129177	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129178	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129179	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129180	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129181	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129182	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129183	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129184	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129185	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129186	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129187	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129188	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129189	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129190	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129191	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129192	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129193	anoikis	NEAT1	PTK2	24297251	starBase v2.0
129194	anoikis	AP000487.1	PTK2	24297251	starBase v2.0
129195	anoikis	AC024230.1	PTK2	24297251	starBase v2.0
129196	anoikis	C5orf17	PTK2	24297251	starBase v2.0
129197	anoikis	PVT1	PTK2	24297251	starBase v2.0
129198	anoikis	PVT1	PTK2	24297251	starBase v2.0
129199	anoikis	PVT1	PTK2	24297251	starBase v2.0
129200	anoikis	PVT1	PTK2	24297251	starBase v2.0
129201	anoikis	PVT1	PTK2	24297251	starBase v2.0
129202	anoikis	PVT1	PTK2	24297251	starBase v2.0
129203	anoikis	PVT1	PTK2	24297251	starBase v2.0
129204	anoikis	PVT1	PTK2	24297251	starBase v2.0
129205	anoikis	PVT1	PTK2	24297251	starBase v2.0
129206	anoikis	PVT1	PTK2	24297251	starBase v2.0
129207	anoikis	PVT1	PTK2	24297251	starBase v2.0
129208	anoikis	PVT1	PTK2	24297251	starBase v2.0
129209	anoikis	PVT1	PTK2	24297251	starBase v2.0
129210	anoikis	PVT1	PTK2	24297251	starBase v2.0
129211	anoikis	PVT1	PTK2	24297251	starBase v2.0
129212	anoikis	PVT1	PTK2	24297251	starBase v2.0
129213	anoikis	PVT1	PTK2	24297251	starBase v2.0
129214	anoikis	PVT1	PTK2	24297251	starBase v2.0
129215	anoikis	PVT1	PTK2	24297251	starBase v2.0
129216	anoikis	PVT1	PTK2	24297251	starBase v2.0
129217	anoikis	AC090578.1	PTK2	24297251	starBase v2.0
129218	anoikis	CASC19	PTK2	24297251	starBase v2.0
129219	anoikis	CASC19	PTK2	24297251	starBase v2.0
129220	anoikis	CASC19	PTK2	24297251	starBase v2.0
129221	anoikis	CASC19	PTK2	24297251	starBase v2.0
129222	anoikis	CASC19	PTK2	24297251	starBase v2.0
129223	anoikis	CASC19	PTK2	24297251	starBase v2.0
129224	anoikis	CASC19	PTK2	24297251	starBase v2.0
129225	anoikis	CASC19	PTK2	24297251	starBase v2.0
129226	anoikis	CASC19	PTK2	24297251	starBase v2.0
129227	anoikis	CASC19	PTK2	24297251	starBase v2.0
129228	anoikis	CASC19	PTK2	24297251	starBase v2.0
129229	anoikis	CASC19	PTK2	24297251	starBase v2.0
129230	anoikis	CASC19	PTK2	24297251	starBase v2.0
129231	anoikis	CASC19	PTK2	24297251	starBase v2.0
129232	anoikis	CASC19	PTK2	24297251	starBase v2.0
129233	anoikis	CASC19	PTK2	24297251	starBase v2.0
129234	anoikis	CASC19	PTK2	24297251	starBase v2.0
129235	anoikis	CASC19	PTK2	24297251	starBase v2.0
129236	anoikis	CASC19	PTK2	24297251	starBase v2.0
129237	anoikis	CASC19	PTK2	24297251	starBase v2.0
129238	anoikis	CASC19	PTK2	24297251	starBase v2.0
129239	anoikis	CASC19	PTK2	24297251	starBase v2.0
129240	anoikis	CASC19	PTK2	24297251	starBase v2.0
129241	anoikis	CASC19	PTK2	24297251	starBase v2.0
129242	anoikis	CASC19	PTK2	24297251	starBase v2.0
129243	anoikis	CASC19	PTK2	24297251	starBase v2.0
129244	anoikis	CASC19	PTK2	24297251	starBase v2.0
129245	anoikis	AC008014.1	PTK2	24297251	starBase v2.0
129246	anoikis	AL160191.1	PTK2	24297251	starBase v2.0
129247	anoikis	MIR23AHG	PTK2	24297251	starBase v2.0
129248	anoikis	AC092279.1	PTK2	24297251	starBase v2.0
129249	anoikis	LINC02664	PTK2	24297251	starBase v2.0
129250	anoikis	AC078846.1	PTK2	24297251	starBase v2.0
129251	anoikis	AC254629.1	PTK2	24297251	starBase v2.0
129252	anoikis	FP671120.4	PTK2	24297251	starBase v2.0
129253	anoikis	BISPR	PTK2	24297251	starBase v2.0
129254	anoikis	AL772307.1	PTK2	24297251	starBase v2.0
129255	anoikis	HULC	PTK2	24297251	starBase v2.0
129256	anoikis	AC093912.1	PTK2	24297251	starBase v2.0
129257	anoikis	SNHG15	PTRH2	24297251	starBase v2.0
129258	anoikis	AC002066.1	PTRH2	24297251	starBase v2.0
129259	anoikis	CDKN2B-AS1	PTRH2	24297251	starBase v2.0
129260	anoikis	MALAT1	PTRH2	24297251	starBase v2.0
129261	anoikis	MIR100HG	PTRH2	24297251	starBase v2.0
129262	anoikis	AC133644.2	SIK1	24297251	starBase v2.0
129263	anoikis	TTTY2B	SRC	24297251	starBase v2.0
129264	anoikis	POLR2J4	SRC	24297251	starBase v2.0
129265	anoikis	SLC16A1-AS1	SRC	24297251	starBase v2.0
129266	anoikis	AL591684.2	SRC	24297251	starBase v2.0
129267	anoikis	AC079313.1	SRC	24297251	starBase v2.0
129268	anoikis	ENTPD1-AS1	SRC	24297251	starBase v2.0
129269	anoikis	FTX	SRC	24297251	starBase v2.0
129270	anoikis	BBOX1-AS1	SRC	24297251	starBase v2.0
129271	anoikis	SNHG1	SRC	24297251	starBase v2.0
129272	anoikis	AC026401.3	SRC	24297251	starBase v2.0
129273	anoikis	RABGAP1L-DT	STK11	24297251	starBase v2.0
129274	anoikis	AL513220.1	STK11	24297251	starBase v2.0
129275	anoikis	FAM153CP	TFDP1	24297251	starBase v2.0
129276	anoikis	POLR2J4	TFDP1	24297251	starBase v2.0
129277	anoikis	ZNF32-AS3	TFDP1	24297251	starBase v2.0
129278	anoikis	LAMTOR5-AS1	TFDP1	24297251	starBase v2.0
129279	anoikis	DLEU2	TFDP1	24297251	starBase v2.0
129280	anoikis	AL078590.2	TFDP1	24297251	starBase v2.0
129281	anoikis	LINC00472	TFDP1	24297251	starBase v2.0
129282	anoikis	NEAT1	TFDP1	24297251	starBase v2.0
129283	anoikis	NEAT1	TFDP1	24297251	starBase v2.0
129284	anoikis	NEAT1	TFDP1	24297251	starBase v2.0
129285	anoikis	NEAT1	TFDP1	24297251	starBase v2.0
129286	anoikis	NEAT1	TFDP1	24297251	starBase v2.0
129287	anoikis	C5orf17	TFDP1	24297251	starBase v2.0
129288	anoikis	AC105460.1	TFDP1	24297251	starBase v2.0
129289	anoikis	AC073530.1	TFDP1	24297251	starBase v2.0
129290	anoikis	AC092142.1	TFDP1	24297251	starBase v2.0
129291	anoikis	AC008982.2	TFDP1	24297251	starBase v2.0
129292	anoikis	SNHG31	TFDP1	24297251	starBase v2.0
129293	anoikis	AC093157.1	TFDP1	24297251	starBase v2.0
129294	anoikis	GAS6-AS1	TFDP1	24297251	starBase v2.0
129295	anoikis	AC107959.2	TFDP1	24297251	starBase v2.0
129296	anoikis	FLJ12825	TFDP1	24297251	starBase v2.0
129297	anoikis	PVT1	TFDP1	24297251	starBase v2.0
129298	anoikis	AC104123.1	TFDP1	24297251	starBase v2.0
129299	anoikis	LINC02615	TFDP1	24297251	starBase v2.0
129300	anoikis	MALAT1	TFDP1	24297251	starBase v2.0
129301	anoikis	MALAT1	TFDP1	24297251	starBase v2.0
129302	anoikis	MALAT1	TFDP1	24297251	starBase v2.0
129303	anoikis	MALAT1	TFDP1	24297251	starBase v2.0
129304	anoikis	MALAT1	TFDP1	24297251	starBase v2.0
129305	anoikis	MIR100HG	TFDP1	24297251	starBase v2.0
129306	anoikis	AC144548.1	TFDP1	24297251	starBase v2.0
129307	anoikis	AC010531.3	TFDP1	24297251	starBase v2.0
129308	anoikis	AC073389.3	TFDP1	24297251	starBase v2.0
129309	anoikis	AP003900.1	TFDP1	24297251	starBase v2.0
129310	anoikis	ZNF337-AS1	TLE1	24297251	starBase v2.0
129311	anoikis	TTN-AS1	TLE1	24297251	starBase v2.0
129312	anoikis	CASC19	TLE1	24297251	starBase v2.0
129313	anoikis	AC090114.2	TLE1	24297251	starBase v2.0
129314	anoikis	AC091078.1	TLE1	24297251	starBase v2.0
129315	anoikis	LINC00482	TSC2	24297251	starBase v2.0
129316	anoikis	COX10-AS1	TSC2	24297251	starBase v2.0
129317	anoikis	LINC01119	TSC2	24297251	starBase v2.0
129318	anoikis	MALAT1	TSC2	24297251	starBase v2.0
129319	anoikis	MALAT1	TSC2	24297251	starBase v2.0
129320	anoikis	MALAT1	TSC2	24297251	starBase v2.0
129321	anoikis	MALAT1	TSC2	24297251	starBase v2.0
129322	anoikis	MALAT1	TSC2	24297251	starBase v2.0
129323	anoikis	MALAT1	TSC2	24297251	starBase v2.0
129324	anoikis	MALAT1	TSC2	24297251	starBase v2.0
129325	anoikis	AL390037.1	TSC2	24297251	starBase v2.0
129326	anoikis	LINC01257	TSC2	24297251	starBase v2.0
129327	anoikis	NEAT1	TSC2	24297251	starBase v2.0
129328	anoikis	NEAT1	TSC2	24297251	starBase v2.0
129329	anoikis	AC008750.6	TSC2	24297251	starBase v2.0
129330	anoikis	LINC00842	TSC2	24297251	starBase v2.0
mirnaid	cdtype	mirna	mitarget	pmid	description
66810	anoikis	hsa-miR-17-5p	ANKRD13C	24297251	starBase v2.0
66811	anoikis	hsa-miR-20a-5p	ANKRD13C	24297251	starBase v2.0
66812	anoikis	hsa-miR-32-5p	ANKRD13C	24297251	starBase v2.0
66813	anoikis	hsa-miR-92a-3p	ANKRD13C	24297251	starBase v2.0
66814	anoikis	hsa-miR-93-5p	ANKRD13C	24297251	starBase v2.0
66815	anoikis	hsa-miR-106a-5p	ANKRD13C	24297251	starBase v2.0
66816	anoikis	hsa-miR-106b-5p	ANKRD13C	24297251	starBase v2.0
66817	anoikis	hsa-miR-302a-3p	ANKRD13C	24297251	starBase v2.0
66818	anoikis	hsa-miR-302b-3p	ANKRD13C	24297251	starBase v2.0
66819	anoikis	hsa-miR-302c-3p	ANKRD13C	24297251	starBase v2.0
66820	anoikis	hsa-miR-302d-3p	ANKRD13C	24297251	starBase v2.0
66821	anoikis	hsa-miR-372-3p	ANKRD13C	24297251	starBase v2.0
66822	anoikis	hsa-miR-373-3p	ANKRD13C	24297251	starBase v2.0
66823	anoikis	hsa-miR-20b-5p	ANKRD13C	24297251	starBase v2.0
66824	anoikis	hsa-miR-495-3p	ANKRD13C	24297251	starBase v2.0
66825	anoikis	hsa-miR-495-3p	ANKRD13C	24297251	starBase v2.0
66826	anoikis	hsa-miR-495-3p	ANKRD13C	24297251	starBase v2.0
66827	anoikis	hsa-miR-520e	ANKRD13C	24297251	starBase v2.0
66828	anoikis	hsa-miR-520a-3p	ANKRD13C	24297251	starBase v2.0
66829	anoikis	hsa-miR-520b	ANKRD13C	24297251	starBase v2.0
66830	anoikis	hsa-miR-520c-3p	ANKRD13C	24297251	starBase v2.0
66831	anoikis	hsa-miR-519d-3p	ANKRD13C	24297251	starBase v2.0
66832	anoikis	hsa-miR-520d-3p	ANKRD13C	24297251	starBase v2.0
66833	anoikis	hsa-miR-92b-3p	ANKRD13C	24297251	starBase v2.0
66834	anoikis	hsa-miR-302e	ANKRD13C	24297251	starBase v2.0
66835	anoikis	hsa-miR-15a-5p	BCL2	24297251	starBase v2.0
66836	anoikis	hsa-miR-16-5p	BCL2	24297251	starBase v2.0
66837	anoikis	hsa-miR-15b-5p	BCL2	24297251	starBase v2.0
66838	anoikis	hsa-miR-195-5p	BCL2	24297251	starBase v2.0
66839	anoikis	hsa-miR-365a-3p	BCL2	24297251	starBase v2.0
66840	anoikis	hsa-miR-374a-5p	BCL2	24297251	starBase v2.0
66841	anoikis	hsa-miR-424-5p	BCL2	24297251	starBase v2.0
66842	anoikis	hsa-miR-497-5p	BCL2	24297251	starBase v2.0
66843	anoikis	hsa-miR-342-3p	BCL2L1	24297251	starBase v2.0
66844	anoikis	hsa-miR-29a-3p	BMF	24297251	starBase v2.0
66845	anoikis	hsa-miR-29b-3p	BMF	24297251	starBase v2.0
66846	anoikis	hsa-miR-29c-3p	BMF	24297251	starBase v2.0
66847	anoikis	hsa-miR-96-5p	CAV1	24297251	starBase v2.0
66848	anoikis	hsa-miR-192-5p	CAV1	24297251	starBase v2.0
66849	anoikis	hsa-miR-7-5p	CAV1	24297251	starBase v2.0
66850	anoikis	hsa-miR-215-5p	CAV1	24297251	starBase v2.0
66851	anoikis	hsa-miR-124-3p	CAV1	24297251	starBase v2.0
66852	anoikis	hsa-miR-128-3p	CAV1	24297251	starBase v2.0
66853	anoikis	hsa-miR-128-3p	CAV1	24297251	starBase v2.0
66854	anoikis	hsa-miR-194-5p	CAV1	24297251	starBase v2.0
66855	anoikis	hsa-miR-302a-3p	CAV1	24297251	starBase v2.0
66856	anoikis	hsa-miR-302b-3p	CAV1	24297251	starBase v2.0
66857	anoikis	hsa-miR-302c-3p	CAV1	24297251	starBase v2.0
66858	anoikis	hsa-miR-302d-3p	CAV1	24297251	starBase v2.0
66859	anoikis	hsa-miR-372-3p	CAV1	24297251	starBase v2.0
66860	anoikis	hsa-miR-373-3p	CAV1	24297251	starBase v2.0
66861	anoikis	hsa-miR-520e	CAV1	24297251	starBase v2.0
66862	anoikis	hsa-miR-520a-3p	CAV1	24297251	starBase v2.0
66863	anoikis	hsa-miR-520b	CAV1	24297251	starBase v2.0
66864	anoikis	hsa-miR-520c-3p	CAV1	24297251	starBase v2.0
66865	anoikis	hsa-miR-520d-3p	CAV1	24297251	starBase v2.0
66866	anoikis	hsa-miR-506-3p	CAV1	24297251	starBase v2.0
66867	anoikis	hsa-miR-340-5p	CAV1	24297251	starBase v2.0
66868	anoikis	hsa-miR-1271-5p	CAV1	24297251	starBase v2.0
66869	anoikis	hsa-miR-302e	CAV1	24297251	starBase v2.0
66870	anoikis	hsa-miR-17-5p	E2F1	24297251	starBase v2.0
66871	anoikis	hsa-miR-17-5p	E2F1	24297251	starBase v2.0
66872	anoikis	hsa-miR-20a-5p	E2F1	24297251	starBase v2.0
66873	anoikis	hsa-miR-20a-5p	E2F1	24297251	starBase v2.0
66874	anoikis	hsa-miR-93-5p	E2F1	24297251	starBase v2.0
66875	anoikis	hsa-miR-93-5p	E2F1	24297251	starBase v2.0
66876	anoikis	hsa-miR-106a-5p	E2F1	24297251	starBase v2.0
66877	anoikis	hsa-miR-106a-5p	E2F1	24297251	starBase v2.0
66878	anoikis	hsa-miR-106b-5p	E2F1	24297251	starBase v2.0
66879	anoikis	hsa-miR-106b-5p	E2F1	24297251	starBase v2.0
66880	anoikis	hsa-miR-302a-3p	E2F1	24297251	starBase v2.0
66881	anoikis	hsa-miR-302b-3p	E2F1	24297251	starBase v2.0
66882	anoikis	hsa-miR-302c-3p	E2F1	24297251	starBase v2.0
66883	anoikis	hsa-miR-302d-3p	E2F1	24297251	starBase v2.0
66884	anoikis	hsa-miR-372-3p	E2F1	24297251	starBase v2.0
66885	anoikis	hsa-miR-373-3p	E2F1	24297251	starBase v2.0
66886	anoikis	hsa-miR-20b-5p	E2F1	24297251	starBase v2.0
66887	anoikis	hsa-miR-20b-5p	E2F1	24297251	starBase v2.0
66888	anoikis	hsa-miR-329-3p	E2F1	24297251	starBase v2.0
66889	anoikis	hsa-miR-520e	E2F1	24297251	starBase v2.0
66890	anoikis	hsa-miR-520a-3p	E2F1	24297251	starBase v2.0
66891	anoikis	hsa-miR-520b	E2F1	24297251	starBase v2.0
66892	anoikis	hsa-miR-520c-3p	E2F1	24297251	starBase v2.0
66893	anoikis	hsa-miR-519d-3p	E2F1	24297251	starBase v2.0
66894	anoikis	hsa-miR-519d-3p	E2F1	24297251	starBase v2.0
66895	anoikis	hsa-miR-520d-3p	E2F1	24297251	starBase v2.0
66896	anoikis	hsa-miR-362-3p	E2F1	24297251	starBase v2.0
66897	anoikis	hsa-miR-302e	E2F1	24297251	starBase v2.0
66898	anoikis	hsa-miR-22-3p	ITGA5	24297251	starBase v2.0
66899	anoikis	hsa-miR-25-3p	ITGA5	24297251	starBase v2.0
66900	anoikis	hsa-miR-26a-5p	ITGA5	24297251	starBase v2.0
66901	anoikis	hsa-miR-26b-5p	ITGA5	24297251	starBase v2.0
66902	anoikis	hsa-miR-28-5p	ITGA5	24297251	starBase v2.0
66903	anoikis	hsa-miR-30a-5p	ITGA5	24297251	starBase v2.0
66904	anoikis	hsa-miR-32-5p	ITGA5	24297251	starBase v2.0
66905	anoikis	hsa-miR-92a-3p	ITGA5	24297251	starBase v2.0
66906	anoikis	hsa-miR-103a-3p	ITGA5	24297251	starBase v2.0
66907	anoikis	hsa-miR-107	ITGA5	24297251	starBase v2.0
66908	anoikis	hsa-miR-148a-3p	ITGA5	24297251	starBase v2.0
66909	anoikis	hsa-miR-148a-3p	ITGA5	24297251	starBase v2.0
66910	anoikis	hsa-miR-30c-5p	ITGA5	24297251	starBase v2.0
66911	anoikis	hsa-miR-30d-5p	ITGA5	24297251	starBase v2.0
66912	anoikis	hsa-miR-30b-5p	ITGA5	24297251	starBase v2.0
66913	anoikis	hsa-miR-128-3p	ITGA5	24297251	starBase v2.0
66914	anoikis	hsa-miR-143-3p	ITGA5	24297251	starBase v2.0
66915	anoikis	hsa-miR-152-3p	ITGA5	24297251	starBase v2.0
66916	anoikis	hsa-miR-152-3p	ITGA5	24297251	starBase v2.0
66917	anoikis	hsa-miR-30e-5p	ITGA5	24297251	starBase v2.0
66918	anoikis	hsa-miR-363-3p	ITGA5	24297251	starBase v2.0
66919	anoikis	hsa-miR-367-3p	ITGA5	24297251	starBase v2.0
66920	anoikis	hsa-miR-328-3p	ITGA5	24297251	starBase v2.0
66921	anoikis	hsa-miR-326	ITGA5	24297251	starBase v2.0
66922	anoikis	hsa-miR-326	ITGA5	24297251	starBase v2.0
66923	anoikis	hsa-miR-148b-3p	ITGA5	24297251	starBase v2.0
66924	anoikis	hsa-miR-148b-3p	ITGA5	24297251	starBase v2.0
66925	anoikis	hsa-miR-92b-3p	ITGA5	24297251	starBase v2.0
66926	anoikis	hsa-miR-296-3p	ITGA5	24297251	starBase v2.0
66927	anoikis	hsa-miR-330-5p	ITGA5	24297251	starBase v2.0
66928	anoikis	hsa-miR-330-5p	ITGA5	24297251	starBase v2.0
66929	anoikis	hsa-miR-708-5p	ITGA5	24297251	starBase v2.0
66930	anoikis	hsa-miR-1297	ITGA5	24297251	starBase v2.0
66931	anoikis	hsa-miR-20a-5p	ITGB1	24297251	starBase v2.0
66932	anoikis	hsa-miR-23a-3p	ITGB1	24297251	starBase v2.0
66933	anoikis	hsa-miR-30a-5p	ITGB1	24297251	starBase v2.0
66934	anoikis	hsa-miR-101-3p	ITGB1	24297251	starBase v2.0
66935	anoikis	hsa-miR-106a-5p	ITGB1	24297251	starBase v2.0
66936	anoikis	hsa-miR-30c-5p	ITGB1	24297251	starBase v2.0
66937	anoikis	hsa-miR-30d-5p	ITGB1	24297251	starBase v2.0
66938	anoikis	hsa-miR-183-5p	ITGB1	24297251	starBase v2.0
66939	anoikis	hsa-miR-183-5p	ITGB1	24297251	starBase v2.0
66940	anoikis	hsa-miR-23b-3p	ITGB1	24297251	starBase v2.0
66941	anoikis	hsa-miR-30b-5p	ITGB1	24297251	starBase v2.0
66942	anoikis	hsa-miR-124-3p	ITGB1	24297251	starBase v2.0
66943	anoikis	hsa-miR-124-3p	ITGB1	24297251	starBase v2.0
66944	anoikis	hsa-miR-124-3p	ITGB1	24297251	starBase v2.0
66945	anoikis	hsa-miR-128-3p	ITGB1	24297251	starBase v2.0
66946	anoikis	hsa-miR-144-3p	ITGB1	24297251	starBase v2.0
66947	anoikis	hsa-miR-153-3p	ITGB1	24297251	starBase v2.0
66948	anoikis	hsa-miR-9-5p	ITGB1	24297251	starBase v2.0
66949	anoikis	hsa-miR-134-5p	ITGB1	24297251	starBase v2.0
66950	anoikis	hsa-miR-320a	ITGB1	24297251	starBase v2.0
66951	anoikis	hsa-miR-106b-5p	ITGB1	24297251	starBase v2.0
66952	anoikis	hsa-miR-30e-5p	ITGB1	24297251	starBase v2.0
66953	anoikis	hsa-miR-499a-5p	ITGB1	24297251	starBase v2.0
66954	anoikis	hsa-miR-506-3p	ITGB1	24297251	starBase v2.0
66955	anoikis	hsa-miR-506-3p	ITGB1	24297251	starBase v2.0
66956	anoikis	hsa-miR-506-3p	ITGB1	24297251	starBase v2.0
66957	anoikis	hsa-miR-874-3p	ITGB1	24297251	starBase v2.0
66958	anoikis	hsa-miR-543	ITGB1	24297251	starBase v2.0
66959	anoikis	hsa-miR-543	ITGB1	24297251	starBase v2.0
66960	anoikis	hsa-miR-320b	ITGB1	24297251	starBase v2.0
66961	anoikis	hsa-miR-320c	ITGB1	24297251	starBase v2.0
66962	anoikis	hsa-miR-320d	ITGB1	24297251	starBase v2.0
66963	anoikis	hsa-miR-103a-3p	MAP3K7	24297251	starBase v2.0
66964	anoikis	hsa-miR-107	MAP3K7	24297251	starBase v2.0
66965	anoikis	hsa-miR-320a	MAP3K7	24297251	starBase v2.0
66966	anoikis	hsa-miR-320b	MAP3K7	24297251	starBase v2.0
66967	anoikis	hsa-miR-320c	MAP3K7	24297251	starBase v2.0
66968	anoikis	hsa-miR-320d	MAP3K7	24297251	starBase v2.0
66969	anoikis	hsa-miR-26a-5p	MCL1	24297251	starBase v2.0
66970	anoikis	hsa-miR-26b-5p	MCL1	24297251	starBase v2.0
66971	anoikis	hsa-miR-29a-3p	MCL1	24297251	starBase v2.0
66972	anoikis	hsa-miR-101-3p	MCL1	24297251	starBase v2.0
66973	anoikis	hsa-miR-29b-3p	MCL1	24297251	starBase v2.0
66974	anoikis	hsa-miR-139-5p	MCL1	24297251	starBase v2.0
66975	anoikis	hsa-miR-217	MCL1	24297251	starBase v2.0
66976	anoikis	hsa-miR-217	MCL1	24297251	starBase v2.0
66977	anoikis	hsa-miR-224-5p	MCL1	24297251	starBase v2.0
66978	anoikis	hsa-miR-125b-5p	MCL1	24297251	starBase v2.0
66979	anoikis	hsa-miR-128-3p	MCL1	24297251	starBase v2.0
66980	anoikis	hsa-miR-153-3p	MCL1	24297251	starBase v2.0
66981	anoikis	hsa-miR-125a-5p	MCL1	24297251	starBase v2.0
66982	anoikis	hsa-miR-186-5p	MCL1	24297251	starBase v2.0
66983	anoikis	hsa-miR-193a-3p	MCL1	24297251	starBase v2.0
66984	anoikis	hsa-miR-320a	MCL1	24297251	starBase v2.0
66985	anoikis	hsa-miR-320a	MCL1	24297251	starBase v2.0
66986	anoikis	hsa-miR-29c-3p	MCL1	24297251	starBase v2.0
66987	anoikis	hsa-miR-361-5p	MCL1	24297251	starBase v2.0
66988	anoikis	hsa-miR-374a-5p	MCL1	24297251	starBase v2.0
66989	anoikis	hsa-miR-448	MCL1	24297251	starBase v2.0
66990	anoikis	hsa-miR-495-3p	MCL1	24297251	starBase v2.0
66991	anoikis	hsa-miR-496	MCL1	24297251	starBase v2.0
66992	anoikis	hsa-miR-193b-3p	MCL1	24297251	starBase v2.0
66993	anoikis	hsa-miR-519d-3p	MCL1	24297251	starBase v2.0
66994	anoikis	hsa-miR-488-3p	MCL1	24297251	starBase v2.0
66995	anoikis	hsa-miR-873-5p	MCL1	24297251	starBase v2.0
66996	anoikis	hsa-miR-374b-5p	MCL1	24297251	starBase v2.0
66997	anoikis	hsa-miR-320b	MCL1	24297251	starBase v2.0
66998	anoikis	hsa-miR-320b	MCL1	24297251	starBase v2.0
66999	anoikis	hsa-miR-320c	MCL1	24297251	starBase v2.0
67000	anoikis	hsa-miR-320c	MCL1	24297251	starBase v2.0
67001	anoikis	hsa-miR-1297	MCL1	24297251	starBase v2.0
67002	anoikis	hsa-miR-320d	MCL1	24297251	starBase v2.0
67003	anoikis	hsa-miR-320d	MCL1	24297251	starBase v2.0
67004	anoikis	hsa-miR-101-3p	NOTCH1	24297251	starBase v2.0
67005	anoikis	hsa-miR-101-3p	NOTCH1	24297251	starBase v2.0
67006	anoikis	hsa-miR-34a-5p	NOTCH1	24297251	starBase v2.0
67007	anoikis	hsa-miR-144-3p	NOTCH1	24297251	starBase v2.0
67008	anoikis	hsa-miR-144-3p	NOTCH1	24297251	starBase v2.0
67009	anoikis	hsa-miR-34c-5p	NOTCH1	24297251	starBase v2.0
67010	anoikis	hsa-miR-449a	NOTCH1	24297251	starBase v2.0
67011	anoikis	hsa-miR-449b-5p	NOTCH1	24297251	starBase v2.0
67012	anoikis	hsa-miR-425-5p	NOTCH1	24297251	starBase v2.0
67013	anoikis	hsa-miR-23a-3p	PDK4	24297251	starBase v2.0
67014	anoikis	hsa-miR-27a-3p	PDK4	24297251	starBase v2.0
67015	anoikis	hsa-miR-23b-3p	PDK4	24297251	starBase v2.0
67016	anoikis	hsa-miR-27b-3p	PDK4	24297251	starBase v2.0
67017	anoikis	hsa-miR-144-3p	PDK4	24297251	starBase v2.0
67018	anoikis	hsa-miR-340-5p	PDK4	24297251	starBase v2.0
67019	anoikis	hsa-miR-17-5p	PTK2	24297251	starBase v2.0
67020	anoikis	hsa-miR-20a-5p	PTK2	24297251	starBase v2.0
67021	anoikis	hsa-miR-93-5p	PTK2	24297251	starBase v2.0
67022	anoikis	hsa-miR-106a-5p	PTK2	24297251	starBase v2.0
67023	anoikis	hsa-miR-221-3p	PTK2	24297251	starBase v2.0
67024	anoikis	hsa-miR-222-3p	PTK2	24297251	starBase v2.0
67025	anoikis	hsa-miR-138-5p	PTK2	24297251	starBase v2.0
67026	anoikis	hsa-miR-193a-3p	PTK2	24297251	starBase v2.0
67027	anoikis	hsa-miR-194-5p	PTK2	24297251	starBase v2.0
67028	anoikis	hsa-miR-106b-5p	PTK2	24297251	starBase v2.0
67029	anoikis	hsa-miR-20b-5p	PTK2	24297251	starBase v2.0
67030	anoikis	hsa-miR-193b-3p	PTK2	24297251	starBase v2.0
67031	anoikis	hsa-miR-519d-3p	PTK2	24297251	starBase v2.0
67032	anoikis	hsa-miR-543	PTK2	24297251	starBase v2.0
67033	anoikis	hsa-miR-17-5p	SIK1	24297251	starBase v2.0
67034	anoikis	hsa-miR-20a-5p	SIK1	24297251	starBase v2.0
67035	anoikis	hsa-miR-25-3p	SIK1	24297251	starBase v2.0
67036	anoikis	hsa-miR-27a-3p	SIK1	24297251	starBase v2.0
67037	anoikis	hsa-miR-32-5p	SIK1	24297251	starBase v2.0
67038	anoikis	hsa-miR-33a-5p	SIK1	24297251	starBase v2.0
67039	anoikis	hsa-miR-92a-3p	SIK1	24297251	starBase v2.0
67040	anoikis	hsa-miR-93-5p	SIK1	24297251	starBase v2.0
67041	anoikis	hsa-miR-106a-5p	SIK1	24297251	starBase v2.0
67042	anoikis	hsa-miR-148a-3p	SIK1	24297251	starBase v2.0
67043	anoikis	hsa-miR-27b-3p	SIK1	24297251	starBase v2.0
67044	anoikis	hsa-miR-130a-3p	SIK1	24297251	starBase v2.0
67045	anoikis	hsa-miR-137	SIK1	24297251	starBase v2.0
67046	anoikis	hsa-miR-137	SIK1	24297251	starBase v2.0
67047	anoikis	hsa-miR-142-3p	SIK1	24297251	starBase v2.0
67048	anoikis	hsa-miR-142-3p	SIK1	24297251	starBase v2.0
67049	anoikis	hsa-miR-152-3p	SIK1	24297251	starBase v2.0
67050	anoikis	hsa-miR-106b-5p	SIK1	24297251	starBase v2.0
67051	anoikis	hsa-miR-302a-3p	SIK1	24297251	starBase v2.0
67052	anoikis	hsa-miR-301a-3p	SIK1	24297251	starBase v2.0
67053	anoikis	hsa-miR-130b-3p	SIK1	24297251	starBase v2.0
67054	anoikis	hsa-miR-363-3p	SIK1	24297251	starBase v2.0
67055	anoikis	hsa-miR-302b-3p	SIK1	24297251	starBase v2.0
67056	anoikis	hsa-miR-302c-3p	SIK1	24297251	starBase v2.0
67057	anoikis	hsa-miR-302d-3p	SIK1	24297251	starBase v2.0
67058	anoikis	hsa-miR-367-3p	SIK1	24297251	starBase v2.0
67059	anoikis	hsa-miR-372-3p	SIK1	24297251	starBase v2.0
67060	anoikis	hsa-miR-373-3p	SIK1	24297251	starBase v2.0
67061	anoikis	hsa-miR-148b-3p	SIK1	24297251	starBase v2.0
67062	anoikis	hsa-miR-384	SIK1	24297251	starBase v2.0
67063	anoikis	hsa-miR-20b-5p	SIK1	24297251	starBase v2.0
67064	anoikis	hsa-miR-495-3p	SIK1	24297251	starBase v2.0
67065	anoikis	hsa-miR-520e	SIK1	24297251	starBase v2.0
67066	anoikis	hsa-miR-520a-3p	SIK1	24297251	starBase v2.0
67067	anoikis	hsa-miR-520b	SIK1	24297251	starBase v2.0
67068	anoikis	hsa-miR-520c-3p	SIK1	24297251	starBase v2.0
67069	anoikis	hsa-miR-519d-3p	SIK1	24297251	starBase v2.0
67070	anoikis	hsa-miR-520d-3p	SIK1	24297251	starBase v2.0
67071	anoikis	hsa-miR-503-5p	SIK1	24297251	starBase v2.0
67072	anoikis	hsa-miR-92b-3p	SIK1	24297251	starBase v2.0
67073	anoikis	hsa-miR-33b-5p	SIK1	24297251	starBase v2.0
67074	anoikis	hsa-miR-454-3p	SIK1	24297251	starBase v2.0
67075	anoikis	hsa-miR-301b-3p	SIK1	24297251	starBase v2.0
67076	anoikis	hsa-miR-302e	SIK1	24297251	starBase v2.0
67077	anoikis	hsa-miR-124-3p	SNAI2	24297251	starBase v2.0
67078	anoikis	hsa-miR-124-3p	SNAI2	24297251	starBase v2.0
67079	anoikis	hsa-miR-124-3p	SNAI2	24297251	starBase v2.0
67080	anoikis	hsa-miR-376c-3p	SNAI2	24297251	starBase v2.0
67081	anoikis	hsa-miR-506-3p	SNAI2	24297251	starBase v2.0
67082	anoikis	hsa-miR-506-3p	SNAI2	24297251	starBase v2.0
67083	anoikis	hsa-miR-506-3p	SNAI2	24297251	starBase v2.0
67084	anoikis	hsa-miR-34a-5p	SRC	24297251	starBase v2.0
67085	anoikis	hsa-miR-34a-5p	SRC	24297251	starBase v2.0
67086	anoikis	hsa-miR-1-3p	SRC	24297251	starBase v2.0
67087	anoikis	hsa-miR-206	SRC	24297251	starBase v2.0
67088	anoikis	hsa-miR-34c-5p	SRC	24297251	starBase v2.0
67089	anoikis	hsa-miR-613	SRC	24297251	starBase v2.0
67090	anoikis	hsa-miR-17-5p	STK11	24297251	starBase v2.0
67091	anoikis	hsa-miR-20a-5p	STK11	24297251	starBase v2.0
67092	anoikis	hsa-miR-93-5p	STK11	24297251	starBase v2.0
67093	anoikis	hsa-miR-106a-5p	STK11	24297251	starBase v2.0
67094	anoikis	hsa-miR-106b-5p	STK11	24297251	starBase v2.0
67095	anoikis	hsa-miR-20b-5p	STK11	24297251	starBase v2.0
67096	anoikis	hsa-miR-519d-3p	STK11	24297251	starBase v2.0
67097	anoikis	hsa-miR-30a-5p	TFDP1	24297251	starBase v2.0
67098	anoikis	hsa-miR-30c-5p	TFDP1	24297251	starBase v2.0
67099	anoikis	hsa-miR-30d-5p	TFDP1	24297251	starBase v2.0
67100	anoikis	hsa-miR-30b-5p	TFDP1	24297251	starBase v2.0
67101	anoikis	hsa-miR-30e-5p	TFDP1	24297251	starBase v2.0
67102	anoikis	hsa-miR-374a-5p	TFDP1	24297251	starBase v2.0
67103	anoikis	hsa-miR-374a-5p	TFDP1	24297251	starBase v2.0
67104	anoikis	hsa-miR-338-3p	TFDP1	24297251	starBase v2.0
67105	anoikis	hsa-miR-410-3p	TFDP1	24297251	starBase v2.0
67106	anoikis	hsa-miR-494-3p	TFDP1	24297251	starBase v2.0
67107	anoikis	hsa-miR-495-3p	TFDP1	24297251	starBase v2.0
67108	anoikis	hsa-miR-374b-5p	TFDP1	24297251	starBase v2.0
67109	anoikis	hsa-miR-374b-5p	TFDP1	24297251	starBase v2.0
celldeathtype	datasource	pathwayname	pathwayid	intersection_num	pathwaygene_num	celldeathgenenum	genesymbols	p_value
84	anoikis	KEGG	EGFR tyrosine kinase inhibitor resistance - Homo sapiens (human)	hsa01521	4	79	29	BCL2L1,PIK3CA,BCL2,SRC	4.96733903854185e-06
85	anoikis	KEGG	Endocrine resistance - Homo sapiens (human)	hsa01522	6	98	29	PIK3CA,BCL2,SRC,E2F1,PTK2,NOTCH1	5.14048625888108e-09
86	anoikis	KEGG	Antifolate resistance - Homo sapiens (human)	hsa01523	1	30	29	IKBKG	0.04262793691251
87	anoikis	KEGG	Platinum drug resistance - Homo sapiens (human)	hsa01524	3	73	29	BCL2L1,PIK3CA,BCL2	0.000159229718881826
88	anoikis	KEGG	Virion - Herpesvirus - Homo sapiens (human)	hsa03266	1	9	29	ITGA5	0.012977146133884
89	anoikis	KEGG	MAPK signaling pathway - Homo sapiens (human)	hsa04010	3	301	29	IKBKG,MAP3K7,NTRK2	0.00923322306637808
90	anoikis	KEGG	ErbB signaling pathway - Homo sapiens (human)	hsa04012	3	85	29	PTK2,PIK3CA,SRC	0.000249926447103754
91	anoikis	KEGG	Ras signaling pathway - Homo sapiens (human)	hsa04014	4	236	29	BCL2L1,PIK3CA,IKBKG,NTRK2	0.000355984124967512
92	anoikis	KEGG	Rap1 signaling pathway - Homo sapiens (human)	hsa04015	3	210	29	PIK3CA,ITGB1,SRC	0.00340962641094777
93	anoikis	KEGG	Chemokine signaling pathway - Homo sapiens (human)	hsa04062	4	192	29	PTK2,PIK3CA,IKBKG,SRC	0.00016201116741299
94	anoikis	KEGG	NF-kappa B signaling pathway - Homo sapiens (human)	hsa04064	4	104	29	BCL2,BCL2L1,IKBKG,MAP3K7	1.48260538652689e-05
95	anoikis	KEGG	HIF-1 signaling pathway - Homo sapiens (human)	hsa04066	2	109	29	PIK3CA,BCL2	0.0108558051124519
96	anoikis	KEGG	FoxO signaling pathway - Homo sapiens (human)	hsa04068	2	131	29	PIK3CA,STK11	0.0153992961023782
97	anoikis	KEGG	Sphingolipid signaling pathway - Homo sapiens (human)	hsa04071	2	121	29	PIK3CA,BCL2	0.0132472650872179
98	anoikis	KEGG	Phospholipase D signaling pathway - Homo sapiens (human)	hsa04072	2	148	29	PIK3CA,TSC2	0.0193770516409286
99	anoikis	KEGG	Cell cycle - Homo sapiens (human)	hsa04110	3	157	29	CHEK2,TFDP1,E2F1	0.00149272589019023
100	anoikis	KEGG	p53 signaling pathway - Homo sapiens (human)	hsa04115	4	74	29	BCL2L1,CHEK2,BCL2,TSC2	3.82310408686415e-06
101	anoikis	KEGG	Mitophagy - animal - Homo sapiens (human)	hsa04137	3	103	29	E2F1,BCL2L1,SRC	0.000439729916103637
102	anoikis	KEGG	Autophagy - animal - Homo sapiens (human)	hsa04140	7	165	29	BCL2L1,PIK3CA,STK11,BCL2,MAP3K7,DAPK2,TSC2	3.06697423013702e-09
103	anoikis	KEGG	Phagosome - Homo sapiens (human)	hsa04145	2	152	29	ITGA5,ITGB1	0.0203696158338221
104	anoikis	KEGG	mTOR signaling pathway - Homo sapiens (human)	hsa04150	3	156	29	PIK3CA,STK11,TSC2	0.00146562577990306
105	anoikis	KEGG	PI3K-Akt signaling pathway - Homo sapiens (human)	hsa04151	11	359	29	ITGA5,BCL2L1,PIK3CA,STK11,IKBKG,BCL2,NTRK2,PTK2,TSC2,MCL1,ITGB1	1.38689060236175e-12
106	anoikis	KEGG	AMPK signaling pathway - Homo sapiens (human)	hsa04152	4	121	29	PIK3CA,STK11,MAP3K7,TSC2	2.69303211554162e-05
107	anoikis	KEGG	Apoptosis - Homo sapiens (human)	hsa04210	5	136	29	BCL2L1,PIK3CA,IKBKG,BCL2,MCL1	1.40648607516169e-06
108	anoikis	KEGG	Longevity regulating pathway - Homo sapiens (human)	hsa04211	3	89	29	PIK3CA,STK11,TSC2	0.000286244205871089
109	anoikis	KEGG	Apoptosis - multiple species - Homo sapiens (human)	hsa04215	2	32	29	BCL2L1,BCL2	0.000980121397337719
110	anoikis	KEGG	Cellular senescence - Homo sapiens (human)	hsa04218	4	156	29	CHEK2,PIK3CA,TSC2,E2F1	7.26616961576054e-05
111	anoikis	KEGG	Wnt signaling pathway - Homo sapiens (human)	hsa04310	2	174	29	TLE1,MAP3K7	0.0261976191452487
112	anoikis	KEGG	Notch signaling pathway - Homo sapiens (human)	hsa04330	2	62	29	TLE1,NOTCH1	0.00363744973586244
113	anoikis	KEGG	Axon guidance - Homo sapiens (human)	hsa04360	4	182	29	PTK2,PIK3CA,ITGB1,SRC	0.000131891054170663
114	anoikis	KEGG	VEGF signaling pathway - Homo sapiens (human)	hsa04370	3	59	29	PTK2,PIK3CA,SRC	8.4369914568061e-05
115	anoikis	KEGG	Osteoclast differentiation - Homo sapiens (human)	hsa04380	3	135	29	PIK3CA,IKBKG,MAP3K7	0.000966496493797542
116	anoikis	KEGG	Focal adhesion - Homo sapiens (human)	hsa04510	7	203	29	ITGA5,PIK3CA,BCL2,SRC,PTK2,CAV1,ITGB1	1.29245631974584e-08
117	anoikis	KEGG	ECM-receptor interaction - Homo sapiens (human)	hsa04512	2	89	29	ITGA5,ITGB1	0.00735271917128499
118	anoikis	KEGG	Adherens junction - Homo sapiens (human)	hsa04520	3	93	29	SNAI2,MAP3K7,SRC	0.000325811183256586
119	anoikis	KEGG	Tight junction - Homo sapiens (human)	hsa04530	3	170	29	STK11,ITGB1,SRC	0.00187406494527331
120	anoikis	KEGG	Platelet activation - Homo sapiens (human)	hsa04611	3	124	29	PIK3CA,ITGB1,SRC	0.000755512862517627
121	anoikis	KEGG	Neutrophil extracellular trap formation - Homo sapiens (human)	hsa04613	3	191	29	PIK3CA,MAP3K7,SRC	0.00260935714312716
122	anoikis	KEGG	Toll-like receptor signaling pathway - Homo sapiens (human)	hsa04620	3	108	29	PIK3CA,IKBKG,MAP3K7	0.000505158644278136
123	anoikis	KEGG	NOD-like receptor signaling pathway - Homo sapiens (human)	hsa04621	4	186	29	BCL2,BCL2L1,IKBKG,MAP3K7	0.000143402081586919
124	anoikis	KEGG	RIG-I-like receptor signaling pathway - Homo sapiens (human)	hsa04622	2	71	29	IKBKG,MAP3K7	0.00474164833021018
125	anoikis	KEGG	C-type lectin receptor signaling pathway - Homo sapiens (human)	hsa04625	3	104	29	PIK3CA,IKBKG,SRC	0.000452350822902847
126	anoikis	KEGG	JAK-STAT signaling pathway - Homo sapiens (human)	hsa04630	4	166	29	BCL2L1,PIK3CA,BCL2,MCL1	9.24518037939137e-05
127	anoikis	KEGG	IL-17 signaling pathway - Homo sapiens (human)	hsa04657	2	94	29	IKBKG,MAP3K7	0.00817041411467789
128	anoikis	KEGG	Th1 and Th2 cell differentiation - Homo sapiens (human)	hsa04658	2	92	29	NOTCH1,IKBKG	0.00783861271830188
129	anoikis	KEGG	T cell receptor signaling pathway - Homo sapiens (human)	hsa04660	3	121	29	PIK3CA,IKBKG,MAP3K7	0.000703616353197711
130	anoikis	KEGG	B cell receptor signaling pathway - Homo sapiens (human)	hsa04662	2	84	29	PIK3CA,IKBKG	0.00657469299218472
131	anoikis	KEGG	TNF signaling pathway - Homo sapiens (human)	hsa04668	3	114	29	PIK3CA,IKBKG,MAP3K7	0.000591535307239544
132	anoikis	KEGG	Leukocyte transendothelial migration - Homo sapiens (human)	hsa04670	3	115	29	PIK3CA,ITGB1,PTK2	0.000606789454330459
133	anoikis	KEGG	Neurotrophin signaling pathway - Homo sapiens (human)	hsa04722	3	119	29	PIK3CA,BCL2,NTRK2	0.000670319691502996
134	anoikis	KEGG	Cholinergic synapse - Homo sapiens (human)	hsa04725	2	113	29	PIK3CA,BCL2	0.011629392530647
135	anoikis	KEGG	Inflammatory mediator regulation of TRP channels - Homo sapiens (human)	hsa04750	2	98	29	PIK3CA,SRC	0.0088527459955009
136	anoikis	KEGG	Regulation of actin cytoskeleton - Homo sapiens (human)	hsa04810	5	229	29	ITGA5,PIK3CA,SRC,PTK2,ITGB1	1.78773602201865e-05
137	anoikis	KEGG	Insulin signaling pathway - Homo sapiens (human)	hsa04910	2	137	29	PIK3CA,TSC2	0.0167580377500822
138	anoikis	KEGG	Estrogen signaling pathway - Homo sapiens (human)	hsa04915	3	137	29	PIK3CA,BCL2,SRC	0.00100846051764136
139	anoikis	KEGG	Prolactin signaling pathway - Homo sapiens (human)	hsa04917	2	70	29	PIK3CA,SRC	0.00461221061384043
140	anoikis	KEGG	Thyroid hormone signaling pathway - Homo sapiens (human)	hsa04919	4	121	29	NOTCH1,PIK3CA,TSC2,SRC	2.69303211554162e-05
141	anoikis	KEGG	Adipocytokine signaling pathway - Homo sapiens (human)	hsa04920	2	69	29	STK11,IKBKG	0.00448444892362865
142	anoikis	KEGG	Relaxin signaling pathway - Homo sapiens (human)	hsa04926	2	129	29	PIK3CA,SRC	0.0149575454033186
143	anoikis	KEGG	AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human)	hsa04933	2	100	29	PIK3CA,BCL2	0.00920320373230843
144	anoikis	KEGG	Growth hormone synthesis, secretion and action - Homo sapiens (human)	hsa04935	2	120	29	PIK3CA,PTK2	0.0130399320502919
145	anoikis	KEGG	Alcoholic liver disease - Homo sapiens (human)	hsa04936	2	142	29	IKBKG,MAP3K7	0.0179281948711649
146	anoikis	KEGG	Prion disease - Homo sapiens (human)	hsa05020	3	272	29	NOTCH1,PIK3CA,CAV1	0.00699978348482944
147	anoikis	KEGG	Bacterial invasion of epithelial cells - Homo sapiens (human)	hsa05100	6	77	29	ITGA5,PIK3CA,SRC,PTK2,CAV1,ITGB1	1.1821352785546e-09
148	anoikis	KEGG	Epithelial cell signaling in Helicobacter pylori infection - Homo sapiens (human)	hsa05120	2	70	29	IKBKG,SRC	0.00461221061384043
149	anoikis	KEGG	Pathogenic Escherichia coli infection - Homo sapiens (human)	hsa05130	4	198	29	IKBKG,MAP3K7,ITGB1,SRC	0.000182309866940455
150	anoikis	KEGG	Shigellosis - Homo sapiens (human)	hsa05131	9	247	29	ITGA5,BCL2L1,PIK3CA,IKBKG,BCL2,SRC,MAP3K7,PTK2,ITGB1	4.66537919407983e-11
151	anoikis	KEGG	Salmonella infection - Homo sapiens (human)	hsa05132	4	249	29	BCL2,PIK3CA,IKBKG,MAP3K7	0.000436028340768613
152	anoikis	KEGG	Pertussis - Homo sapiens (human)	hsa05133	2	76	29	ITGA5,ITGB1	0.0054138101772927
153	anoikis	KEGG	Yersinia infection - Homo sapiens (human)	hsa05135	7	137	29	ITGA5,PIK3CA,IKBKG,SRC,MAP3K7,PTK2,ITGB1	8.34630808910219e-10
154	anoikis	KEGG	Leishmaniasis - Homo sapiens (human)	hsa05140	2	77	29	MAP3K7,ITGB1	0.00555320390728198
155	anoikis	KEGG	Chagas disease - Homo sapiens (human)	hsa05142	2	102	29	PIK3CA,IKBKG	0.00955980774453824
156	anoikis	KEGG	Toxoplasmosis - Homo sapiens (human)	hsa05145	5	111	29	BCL2L1,IKBKG,BCL2,MAP3K7,ITGB1	5.13529308410199e-07
157	anoikis	KEGG	Amoebiasis - Homo sapiens (human)	hsa05146	2	102	29	PIK3CA,PTK2	0.00955980774453824
158	anoikis	KEGG	Tuberculosis - Homo sapiens (human)	hsa05152	2	180	29	BCL2,SRC	0.0278918703530022
159	anoikis	KEGG	Hepatitis C - Homo sapiens (human)	hsa05160	3	158	29	PIK3CA,IKBKG,E2F1	0.0015201397122524
160	anoikis	KEGG	Hepatitis B - Homo sapiens (human)	hsa05161	6	162	29	PIK3CA,IKBKG,BCL2,SRC,MAP3K7,E2F1	1.04789650956505e-07
161	anoikis	KEGG	Measles - Homo sapiens (human)	hsa05162	5	138	29	BCL2L1,PIK3CA,IKBKG,BCL2,MAP3K7	1.51160636252534e-06
162	anoikis	KEGG	Human cytomegalovirus infection - Homo sapiens (human)	hsa05163	6	225	29	PIK3CA,IKBKG,SRC,E2F1,PTK2,TSC2	7.25606325246986e-07
163	anoikis	KEGG	Influenza A - Homo sapiens (human)	hsa05164	2	171	29	PIK3CA,IKBKG	0.0253670007058489
164	anoikis	KEGG	Human papillomavirus infection - Homo sapiens (human)	hsa05165	8	331	29	ITGA5,PIK3CA,IKBKG,E2F1,PTK2,NOTCH1,TSC2,ITGB1	1.64023792326162e-08
165	anoikis	KEGG	Human T-cell leukemia virus 1 infection - Homo sapiens (human)	hsa05166	5	222	29	BCL2L1,PIK3CA,IKBKG,E2F1,CHEK2	1.53934524076416e-05
166	anoikis	KEGG	Kaposi sarcoma-associated herpesvirus infection - Homo sapiens (human)	hsa05167	4	194	29	E2F1,PIK3CA,IKBKG,SRC	0.000168585268434995
167	anoikis	KEGG	Herpes simplex virus 1 infection - Homo sapiens (human)	hsa05168	8	512	29	ITGA5,BCL2L1,PIK3CA,IKBKG,BCL2,SRC,MAP3K7,TSC2	4.66827503764478e-07
168	anoikis	KEGG	Epstein-Barr virus infection - Homo sapiens (human)	hsa05169	5	202	29	PIK3CA,IKBKG,BCL2,MAP3K7,E2F1	9.75168322780995e-06
169	anoikis	KEGG	Human immunodeficiency virus 1 infection - Homo sapiens (human)	hsa05170	6	212	29	BCL2L1,PIK3CA,IKBKG,BCL2,MAP3K7,PTK2	5.12167119159912e-07
170	anoikis	KEGG	Coronavirus disease - COVID-19 - Homo sapiens (human)	hsa05171	3	232	29	PIK3CA,IKBKG,MAP3K7	0.00450650991621404
171	anoikis	KEGG	Pathways in cancer - Homo sapiens (human)	hsa05200	9	531	29	BCL2L1,PIK3CA,IKBKG,BCL2,E2F1,PTK2,DAPK2,NOTCH1,ITGB1	3.82168909851544e-08
172	anoikis	KEGG	Transcriptional misregulation in cancer - Homo sapiens (human)	hsa05202	2	193	29	BCL2L1,PTK2	0.0317102834928707
173	anoikis	KEGG	Viral carcinogenesis - Homo sapiens (human)	hsa05203	3	204	29	PIK3CA,IKBKG,SRC	0.00314255904796334
174	anoikis	KEGG	Proteoglycans in cancer - Homo sapiens (human)	hsa05205	6	205	29	ITGA5,PIK3CA,SRC,PTK2,CAV1,ITGB1	4.20595263728174e-07
175	anoikis	KEGG	MicroRNAs in cancer - Homo sapiens (human)	hsa05206	7	310	29	ITGA5,PIK3CA,BCL2,BMF,E2F1,NOTCH1,MCL1	2.33978565411519e-07
176	anoikis	KEGG	Chemical carcinogenesis - receptor activation - Homo sapiens (human)	hsa05207	4	212	29	E2F1,PIK3CA,BCL2,SRC	0.000236749703235395
177	anoikis	KEGG	Chemical carcinogenesis - reactive oxygen species - Homo sapiens (human)	hsa05208	4	223	29	PTK2,PIK3CA,IKBKG,SRC	0.000287077658577939
178	anoikis	KEGG	Colorectal cancer - Homo sapiens (human)	hsa05210	2	86	29	PIK3CA,BCL2	0.00688110626857108
179	anoikis	KEGG	Pancreatic cancer - Homo sapiens (human)	hsa05212	4	76	29	BCL2L1,PIK3CA,IKBKG,E2F1	4.25432799044945e-06
180	anoikis	KEGG	Glioma - Homo sapiens (human)	hsa05214	2	75	29	PIK3CA,E2F1	0.00527606390853308
181	anoikis	KEGG	Prostate cancer - Homo sapiens (human)	hsa05215	4	97	29	PIK3CA,IKBKG,BCL2,E2F1	1.1250449261313e-05
182	anoikis	KEGG	Melanoma - Homo sapiens (human)	hsa05218	2	72	29	PIK3CA,E2F1	0.00487275728816405
183	anoikis	KEGG	Bladder cancer - Homo sapiens (human)	hsa05219	3	41	29	E2F1,DAPK2,SRC	2.8155214527037e-05
184	anoikis	KEGG	Chronic myeloid leukemia - Homo sapiens (human)	hsa05220	4	76	29	BCL2L1,PIK3CA,IKBKG,E2F1	4.25432799044945e-06
185	anoikis	KEGG	Acute myeloid leukemia - Homo sapiens (human)	hsa05221	2	67	29	PIK3CA,IKBKG	0.00423397280768045
186	anoikis	KEGG	Small cell lung cancer - Homo sapiens (human)	hsa05222	7	92	29	BCL2L1,PIK3CA,IKBKG,BCL2,E2F1,PTK2,ITGB1	4.96530594418232e-11
187	anoikis	KEGG	Non-small cell lung cancer - Homo sapiens (human)	hsa05223	2	72	29	PIK3CA,E2F1	0.00487275728816405
188	anoikis	KEGG	Breast cancer - Homo sapiens (human)	hsa05224	3	147	29	NOTCH1,PIK3CA,E2F1	0.00123561301358932
189	anoikis	KEGG	Hepatocellular carcinoma - Homo sapiens (human)	hsa05225	3	168	29	BCL2L1,PIK3CA,E2F1	0.00181182891796228
190	anoikis	KEGG	Gastric cancer - Homo sapiens (human)	hsa05226	3	149	29	PIK3CA,BCL2,E2F1	0.00128459275829429
191	anoikis	KEGG	Choline metabolism in cancer - Homo sapiens (human)	hsa05231	2	98	29	PIK3CA,TSC2	0.0088527459955009
192	anoikis	KEGG	PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)	hsa05235	2	89	29	PIK3CA,IKBKG	0.00735271917128499
193	anoikis	KEGG	Hypertrophic cardiomyopathy - Homo sapiens (human)	hsa05410	2	97	29	ITGA5,ITGB1	0.00867983327321409
194	anoikis	KEGG	Arrhythmogenic right ventricular cardiomyopathy - Homo sapiens (human)	hsa05412	2	84	29	ITGA5,ITGB1	0.00657469299218472
195	anoikis	KEGG	Dilated cardiomyopathy - Homo sapiens (human)	hsa05414	2	103	29	ITGA5,ITGB1	0.00974040334510129
196	anoikis	KEGG	Diabetic cardiomyopathy - Homo sapiens (human)	hsa05415	2	203	29	PDK4,PIK3CA	0.034780710694656
197	anoikis	KEGG	Lipid and atherosclerosis - Homo sapiens (human)	hsa05417	7	215	29	BCL2L1,PIK3CA,IKBKG,BCL2,SRC,MAP3K7,PTK2	1.92098557061371e-08
198	anoikis	KEGG	Fluid shear stress and atherosclerosis - Homo sapiens (human)	hsa05418	7	139	29	PIK3CA,IKBKG,BCL2,SRC,MAP3K7,PTK2,CAV1	9.24066378971133e-10
substance_id	chemicals	cdtype	type	pmid	description
26	caspase-3	anoikis	inducer	23830918	As described above, both extrinsic and intrinsic apoptotic pathways merge at and rely on the activation of the effector caspase-3, which initiates a downstream proteolytic cascade to effect cell death. 
27	EGFR	anoikis	inhibitor	36230714	EGFR has crosstalk through cell-adhering proteins or inhibits apoptosis signaling to inhibit anoikis. 
28	DAPK	anoikis	inducer	36230714	DAPK is a Ser/Thr protein kinase that mediates apoptosis signaling with upregulation of interferon-, tumor necrosis factor-, and Fas to initiate apoptosis and anoikis
29	 BIM 	anoikis	inducer	36230714	The pro-apoptotic protein BIM, a BH3-only protein, is a critical executor of apoptosis in anoikis. BIM disrupts the outer mitochondrial membrane to induce apoptosis, a response to anchorage-independent growth [119].
30	Tunicamycin	anoikis	inducer	37667281	Tunicamycin is a substance that induces endoplasmic reticulum stress by blocking the protein N-glycosylation process. This can cause an accumulation of misfolded proteins, leading to protein aggregation and ultimately, cell death through a process called anoikis 
31	Staurosporine	anoikis	inducer	37667281	Staurosporine is an alkaloid that was first isolated from Streptomyces staurosporeus in 1977. It is a non-specific inhibitor of various kinases and has been shown to induce apoptosis in many types of cancer cells, including cervical cancer. 
32	Bcl-2	anoikis	inhibitor	36030535	Bcl-2 prevents Bak and Bax oligomerization after binding to them, inhibiting them and preserving mitochondrial membrane integrity (Chiarugi & Giannoni, 2008). Thus, by inhibiting the antiapoptotic Bcl-2 family, the mitochondrial-dependent intrinsic pathway can be strengthened even further.
33	Bid	anoikis	inducer	36030535	Bid and Bim (two BH3-only proapoptotic Bcl-2 family members) are activated, causing Bax and Bak (two multidomain proapoptotic Bcl-2 family members) to form oligomers within the outer membrane of the mitochondria, resulting in membrane perforation and the entry of cytochrome c, as well as other agents, into the cytoplasm. 
34	Bim	anoikis	inducer	36030535	Bid and Bim (two BH3-only proapoptotic Bcl-2 family members) are activated, causing Bax and Bak (two multidomain proapoptotic Bcl-2 family members) to form oligomers within the outer membrane of the mitochondria, resulting in membrane perforation and the entry of cytochrome c, as well as other agents, into the cytoplasm. 
35	ECM detachment	anoikis	inhibitor	 37537585	Expression of several pro-apoptotic BH3-only proteins of the Bcl-2 family is downregulated following ECM detachment, resulting in an intrinsic cell death cascade. 
36	Hypoxia 	anoikis	inhibitor	 37537585	Hypoxia contributes to blocking the expression of pro-apoptotic BH3 family members, such as Bim and Bmf, in epithelial cells .
37	CXCL12、CCL19/CCL21	anoikis	inhibitor	 37537585	Activation of CCR4 and CCR7 by their respective chemokine ligands CXCL12, CCL19/CCL21 downregulates pro-apoptotic Bmf and upregulates pro-survival proteins Bcl-2 and Bcl-xL, 
38	caspase-8（attaches to FADD） 	anoikis	inducer	 28836703	caspase-8  attaches to FADD (Fas-associated death domain) and could induce DISC (death-inducing signaling complex) formation, trigger caspase-8, and effector caspase-3 activation which initiates a downstream proteolytic cascade to start cell death.
39	Bcl-2	anoikis	inhibitor	 28836703	Activation of Bcl-2 (B-cell lymphoma 2) anti-apoptotic protein, pro-survival pathways, and down-regulation of pro-apoptotic proteins like p21 and NOXA by EMT transcription factors including SNAIL, TWIST, and ZEB1/2. 
40	SNAIL、TWIST 和 ZEB1/2	anoikis	inhibitor	 28836703	Activation of Bcl-2 (B-cell lymphoma 2) anti-apoptotic protein, pro-survival pathways, and down-regulation of pro-apoptotic proteins like p21 and NOXA by EMT transcription factors including SNAIL, TWIST, and ZEB1/2. 
41	FAK molecules	anoikis	inhibitor	 28836703	FAK molecules could activate MAPK (mitogen activated protein kinase) and PI3K(phosphoinositide-3-OH kinase)/AKT signaling pathway that are able to stimulate cell survival via inactivation of apoptotic agent's and increasing of pro-survival proteins.
42	Cell-contact related proteins 	anoikis	inhibitor	 28836703	Cell-contact related proteins such as cadherins and selectins launch a network of pathways that could be related with survival via affecting on PI3-K and MAPK and indirectly motivate integrin pathway associated with the survival. 
43	Death-inducing signaling complex 	anoikis	inducer	37091854	The death-inducing signaling complex (DISC) is formed when death effector domain (DED) of FAS-associated death domain (FADD) binds with caspase-8 (FLICE). FLICE when released into the cytoplasm cleaves caspase-3 and caspase-7 followed by cell death of cellular substrates 
44	FLICE-inhibitory protein (FLIP)	anoikis	inhibitor	37091854	FLICE-inhibitory protein (FLIP) inhibits caspase-8 binding and activation by having preferential affinity for DISC.
45	Par-4	anoikis	inducer	37091854	Compelling evidence linking anoikis and EMT stems from studies on prostate apoptosis response-4 (Par-4), a tumor suppressor which selectively induces apoptosis via caspase-dependent mechanisms in cancer cells but not normal cells
46	Cyt c	anoikis	inducer	36046036	Cyt c is the main contributor to the intrinsic pathway, and its leakage leads to the formation of apoptosomes with apoptotic protease activating factor-1 (Apaf-1), thereby activating Caspase-9. EndoG and AIF participate in Caspase-independent DNA fragmentation. Smac and HtrA2 activate Caspase by neutralizing the apoptosis inhibitor IAP. These proteins eventually lead to anoikis via different mechanisms
47	Integrins' interaction （with ECM proteins）	anoikis	inhibitor	36046036	Finally, the overall interplay of activated integrin-dependent survival signaling complexes in detached cells, including ERK/MAPK, PI3K/AKT, and Janus kinase (JNK), together with inhibitory apoptotic signaling determines the cell's fate toward either anoikis resistance/survival or anoikis apoptosis death. For instance, the activated ERK pathway is able to suppress apoptosis pathways, resulting in anoikis-resistance phenotypes 
48	ras	anoikis	inhibitor	11544023	 Because ras activation prevents anoikis 
49	IGFs 	anoikis	inhibitor	11544023	Two studies demonstrated that although IGFs protected serum-starved mouse embryo fibroblasts [21] and LNCap prostate carcinoma cells [22] from anoikis,
50	Bax	anoikis	inducer	37181747	Following cellular detachment, the pro-apoptotic members translocate from the cytosol to the mitochondria where they cause mitochondrial outer-membrane permeabilisation (MOMP) and cytochrome c release, triggering apoptosome assembly, caspase cleavage and cell death
51	Bak	anoikis	inducer	37181747	Following cellular detachment, the pro-apoptotic members translocate from the cytosol to the mitochondria where they cause mitochondrial outer-membrane permeabilisation (MOMP) and cytochrome c release, triggering apoptosome assembly, caspase cleavage and cell death
52	Bok	anoikis	inducer	37181747	Following cellular detachment, the pro-apoptotic members translocate from the cytosol to the mitochondria where they cause mitochondrial outer-membrane permeabilisation (MOMP) and cytochrome c release, triggering apoptosome assembly, caspase cleavage and cell death
53	Bcl-2	anoikis	inhibitor	37181747	The Bcl-2 family of proteins play a key role in both apoptosis pathways and is comprised of three subgroups: the anti-apoptotic proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1) 
54	Bcl-XL	anoikis	inhibitor	37181747	The Bcl-2 family of proteins play a key role in both apoptosis pathways and is comprised of three subgroups: the anti-apoptotic proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1) 
55	Bcl-w	anoikis	inhibitor	37181747	The Bcl-2 family of proteins play a key role in both apoptosis pathways and is comprised of three subgroups: the anti-apoptotic proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1) 
56	Mcl-1	anoikis	inhibitor	37181747	The Bcl-2 family of proteins play a key role in both apoptosis pathways and is comprised of three subgroups: the anti-apoptotic proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1) 
57	A1	anoikis	inhibitor	37181747	The Bcl-2 family of proteins play a key role in both apoptosis pathways and is comprised of three subgroups: the anti-apoptotic proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1) 
58	EMT	anoikis	inhibitor	37181747	 EMT allows epithelial cells to gain reversible migratory and invasive properties, as well as stem cell-ness and the ability to evade apoptosis with the loss of cell-to-cell adhesion in response to microenvironmental cues
59	αvβ3 integrin	anoikis	inhibitor	37181747	To date, the most comprehensively studied integrin with links to anoikis resistance in melanoma metastasis is the 伪v尾3 integrin
60	ADH-1	anoikis	inducer	37181747	ADH-1 (exherin) is a synthetic cyclic peptide containing the His-Ala-Val (HAV) sequence (N-Ac-CHAVC-NH2), designed to bind and inhibit N-cadherin clustering and interactions (Eslami et al., 2019), inhibiting angiogenesis and metastasis, and promoting apoptosis in multiple myeloma, neuroblastoma and pancreatic cancer
61	Focal adhesion kinase	anoikis	inducer	21114588	 Disrupting FAK signaling and genetic deletion of FAK induce anoikis and apoptosis in cells (Taylor et al, 2008; Schwock et al, 2009). Furthermore, anoikis is associated with reduced levels of FAK phosphorylation in multiple cell types including OSCC
62	syndecan-2	anoikis	inducer	21114588	Alterations in syndecan-2 levels can also regulate cancer cell apoptosis
63	syndecans	anoikis	inducer	21114588	Syndecans interact with a number of ECM ligands including fibroblast growth factor, vascular endothelial growth factor, transforming growth factor-beta, epithelial growth factor, and fibronectin (Tkachenko et al, 2005). In many cell models, overexpression of syndecans enhances cell adhesion and migration in normal and neoplastic cells, whereas interference with syndecan function decreases cell migration, consequently enhancing cell spreading
64	cell surface death receptors（ Fas/CD95, TNFR1, TNFR2, DR4）	anoikis	inducer	21114588	In the extrinsic pathway, cell surface death receptors, such as Fas/CD95, TNFR1, TNFR2, DR4, and DR5, are characterized by the presence of a death domain and are activated by extracellular death ligands.
65	DNA damage or cytokine deprivation	anoikis	inducer	21114588	The intrinsic pathway is mediated by intracellular signals induced by DNA damage or cytokine deprivation leading to caspase activation and cell death
66	Oat avenanthramides	anoikis	inducer	35955669	Avena sativa L. is a wholegrain cereal and an important edible crop. Oats possesses high nutritional and health promoting values and contains high levels of bioactive compounds, including a group of phenolic amides, named avenanthramides (Avns), exerting antioxidant, anti-inflammatory, and anticancer activities. Epidermal growth factor receptor (EGFR) represents one of the most known oncogenes and it is frequently up-regulated or mutated in human cancers. The oncogenic effects of EGFR include enhanced cell growth, angiogenesis, and metastasis, and down-regulation or inhibition of EGFR signaling has therapeutic benefit. Front-line EGFR tyrosine kinase inhibitor therapy is the standard therapy for patients with EGFR-mutated lung cancer. However, the clinical effects of EGFR inhibition may be lost after a few months of treatment due to the onset of resistance. Here, we showed the anticancer activity of Avns, focusing on EGFR activation and signaling pathway. Lung cancer cellular models have been used to evaluate the activity of Avns on tumor growth, migration, EMT, and anoikis induced by EGF. In addition, docking and molecular dynamics simulations showed that the Avns bind with high affinity to a region in the vicinity of αC-helix and the DGF motif of EGFR, jeopardizing the target biological function. Altogether, our results reveal a new pharmacological activity of Avns as EGFR tyrosine kinase inhibitors.
67	Jinfukang	anoikis	inducer	33068649	Jinfukang could inhibit the proliferation, migration and invasion of CTC-TJH-01 and H1975 cells. Besides, Jinfukang could also induce anoikis in CTC-TJH-01 and H1975 cells. Analysis of the mRNA expression profile showed ECM-receptor interaction and focal adhesion were regulated by Jinfukang. Moreover, it was also find that Jinfukang significantly inhibited integrin/Src pathway in CTC-TJH-01 and H1975 cells. When suppress the expression of integrin with ATN-161, it could promote Jinfukang to inhibit migration and induce anoikis in CTC-TJH-01 and H1975 cells.
68	Modified Bu-Fei decoction	anoikis	inhibitor	36070661	MBFD significantly suppressed spontaneous lung metastasis of LLC tumors, but not tumor growth, at clinically relevant concentrations. The anti-metastatic effects of MBFD were verified in metastatic cancer models created by intravenous injection of LLC or 4T1 cells. MBFD inhibited lung infiltration of circulating tumor cells, without reducing tumor cell proliferations in lung. In vitro, MBFD dose-dependently inhibited trans-endothelial migrations of tumor cells. RNA-seq assay and verification experiments confirmed that MBFD potently depressed endothelial ANGPTL4 which is able to broke endothelial barrier and protect tumor cells from anoikis. Database analysis revealed that high ANGPTL4 levels is negatively correlated with overall survival of cancer patients. Importantly, MBFD therapy reduced plasma levels of ANGPTL4 in lung cancer patients. Finally, MBFD was revealed to inhibit ANGPTL4 expressions in a hypoxia inducible factor-1α (HIF-1α)-dependent manner, based on results from specific signaling inhibitors and network pharmacology analysis.
69	ABT-263	anoikis	inducer	21206976	The tyrosine kinase Src plays an important role in the development of anoikis resistance in lung adenocarcinomas. Several suspension lung adenocarcinoma cell lines, which express phosphorylated Src, undergo apoptosis, or anoikis, in the presence of Src kinase inhibitors. However, lung adenocarcinoma cell lines vary in their sensitivity to Src inhibitors. We hypothesized that the addition of ABT-263, a potent Bcl-2 inhibitor, should significantly enhance the degree of anoikis in lung adenocarcinoma cells treated with Src inhibitors. In this study, we treated four suspension lung adenocarcinoma cell lines with ABT-263, an Src inhibitor (bosutinib or PP1), or a combination of both. In LC-KJ and HCC827 cells, combined treatment with ABT-263 and an Src inhibitor effectively induced anoikis, and the extent of anoikis was significantly greater than that induced by each agent alone; the synergy between the two drugs was apparent. Although we did not observe a marked increase in anoikis in LC-KJ and HCC827 cells treated with ABT-263 alone, H1650 and H1975 cells treated with ABT-263 (1 μM) upon detachment significantly underwent apoptosis, the levels of which were much greater than those observed upon attachment. However, the levels of anoikis induced by combination treatment were still greater than those by the individual agents in H1650 and H1975 cells. These findings provide a biological rationale to test combination therapy with ABT-263 and Src inhibitors in patients with lung adenocarcinoma.
70	WZ4002	anoikis	inducer	22157722	Src has a role in the anoikis resistance in lung adenocarcinomas. We focused on two epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma cell lines, HCC827 (E746-A750 deletion) and H1975 (L858R+T790M), in suspension to elucidate whether suspended lung adenocarcinoma cells are eradicated by long-term treatment with Src tyrosine kinase inhibitors (TKIs). We also examined metastasis-positive lymph nodes from 16 EGFR-mutant lung adenocarcinoma patients for immunohistochemical expression of mutant-specific EGFR. Almost all suspended HCC827 cells underwent apoptosis after 144 h of combination treatment with AZD0530, trichostatin A (TSA), and ABT-263, whereas many suspended H1975 cells survived the treatment. AZD0530 is a Src TKI, TSA is a histone deacetylase inhibitor, and ABT-263 is a Bcl-2 inhibitor. During the therapy, the phosphorylation of EGFR decreased in HCC827 cells and remained stable in H1975 cells. The phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, was completely suppressed by the third generation EGFR TKI, WZ4002. Consequently, both the suspended cell lines were almost completely eradicated within 144 h, with the combined therapy of WZ4002, ABT-263, and TSA. Interestingly, treated suspended cells underwent apoptosis to a greater extent than did adherent cells. Intrasinus floating lung adenocarcinoma cells in the lymph nodes expressed a mutant-specific EGFR. These findings suggest that suspended EGFR-mutant lung adenocarcinoma cells depend significantly more on EGFR activation for survival than attached cells do. The tumor cells circulating in vessels, which express mutant-specific EGFR, would be highly susceptible to the combination therapy of WZ4002, ABT-263, and TSA.
71	KRT1853	anoikis	inducer	31292507	Elevated expression of transmembrane serine protease 4 (TMPRSS4) correlates with poor prognosis in non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and other cancer patients. Previously, we demonstrated that TMPRSS4 mediates tumor cell invasion, migration, proliferation, and metastasis. In addition, we reported novel 2-hydroxydiarylamide derivatives, IMD-0354 and KRT1853, as TMPRSS4 serine protease inhibitors. Here, we further evaluated the effects of the representative derivatives on TMPRSS4-mediated cellular function and signaling. IMD-0354 and KRT1853 inhibited cancer cell invasion, migration, and proliferation in TMPRSS4-expressing prostate, colon, and lung cancer cells. Both compounds suppressed TMPRSS4-mediated induction of Sp1/3, AP-1, and NF-κB transcription factors. Furthermore, TMPRSS4 promoted cancer cell survival and drug resistance, and both compounds enhanced anoikis sensitivity as well as reduced bcl-2 and survivin levels. Importantly, KRT1853 efficiently reduced tumor growth in prostate and colon cancer xenograft models. These results strongly recommend KRT1853 for further development as a novel anti-cancer agent. 
72	Nintedanib	anoikis	inducer	27133742	Tumor and normal supernatants demonstrated similar pro-metastatic effects on the NSCLC phenotype: both elevated cancer cell number, PCNA levels, reduced total and apoptotic cell death and facilitated cell migration. Nintedanib had limited but significant effects on the NSCLC cell number, cell death and migration, but required high doses. However, at lower doses Nintedanib caused cell detachment and elevated integrin-alpha 5 and EGFR levels, both markers of anoikis resistance. This suggests them as possible targets in combination with Nintedanib. Moreover, Nintedanib completely blocked the supernatants ability to facilitate the aggressive cancer cell characteristics. While cytokine array analysis showed no significant changes in FGF, PDGF or VEGF, we found that both supernatants contained high HGF levels, suggesting it as the facilitator of cell migration and proliferation.
73	Renieramycin M	anoikis	inducer	27069144	Anoikis resistance in H460 cells is mediated through the up-regulation of survival and anti-apoptotic proteins, namely phosphorylated extracellular signal-regulated kinase (p-ERK), phosphorylated ATP-dependent tyrosine kinase (p-AKT), B-cell lymphoma-2 (BCL2), and myeloid cell leukemia-1 (MCL1). RM significantly reduced cell viability and inhibited spontaneous aggregation of AR_H460 cells. Western blot analysis revealed that RM suppressed the levels of survival proteins p-ERK and p-AKT and anti-apoptotic proteins BCL2 and MCL1.
74	Avicequinone B	anoikis	inducer	29631569	Avicequinone B at 4 μM significantly induced anoikis and inhibited proliferation under detachment condition in various human lung cancer cells. The reduction of anti-apoptotic proteins including anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia 1 (Mcl-1) associating with the diminution of integrin/focal adhesion kinase (FAK)/Proto-oncogene tyrosine-protein kinase (Src) signals were detected in avicequinone B-treated cells.
75	Carbenoxolone	anoikis	inhibitor	31533288	Carbenoxolone is an anti-inflammatory compound and a derivate of a natural substance from the licorice plant. We previously showed that carbenoxolone reduces the metastatic burden in the lungs of mice through its antagonistic effect on high mobility group box 1 (HMGB1). To further enhance carbenoxolone's activity and localization in the lungs, thereby reducing the potential adverse side effects resulting from systemic exposure, we developed a poly(lactic-co-glycolic acid) (PLGA) slow-release system for pulmonary delivery which maintains drug activity in-vitro, as demonstrated in the anoikis assay. Both systemic and intranasal administrations of carbenoxolone effectively minimize metastatic formation in a lung colonization model in mice. Our results show a decrease in the metastatic burden in the lung tissue. Notably, the therapeutic effect of a single intranasal administration of 25 mg/kg carbenoxolone, in the form of drug-loaded particles, had a similar effect in reducing metastatic lesions in the lungs to that of a 10-fold dose of the free drug via intraperitoneal injections, three times per week over the course of four weeks. These data offer new means to potentiate the anti-cancer activity of carbenoxolone and simultaneously reduce the requirement for high dosage administration; the upshot substantially improves therapeutic effect and avoidance of side effects.
76	D6-MA	anoikis	inducer	24231508	Advanced stage cancers acquire anoikis resistance which provides metastatic potential to invade and form tumors at distant sites. Suppression of anoikis resistance by novel molecular therapies would greatly benefit treatment strategies for metastatic cancers. Recently, digitoxin and several of its novel synthetic derivatives, such as α-l-rhamnose monosaccharide derivative (D6-MA), have been synthesized and studied for their profound anticancer activity in various cancer cell lines. In this study, we investigated the anoikis sensitizing effect of D6-MA compared with digitoxin to identify their anti-metastatic mechanism of action. D6-MA sensitized NSCLC H460 cells to detachment-induced apoptosis with significantly greater cytotoxicity (IC50=11.9 nM) than digitoxin (IC50=90.7 nM) by activating caspase-9. Screening of the Bcl-2 protein family revealed that degradation of anti-apoptotic Mcl-1 protein is a favorable target. Mcl-1 over-expression and knockdown studies in D6-MA and digitoxin exposed cells resulted in rescue and enhancement, respectively, indicating a facilitative role for decreased Mcl-1 expression in NSCLC anoikis. Transfection with mutant Mcl-1S159 attenuated detachment-induced cell death and correlated with a remaining of Mcl-1 level. Furthermore, D6-MA suppressed Mcl-1 expression via ubiquitin proteasomal degradation that is dependent on activation of glycogen synthase kinase (GSK)-3β signaling. In addition, D6-MA also targeted Mcl-1 degradation causing an increased anoikis in A549 lung cancer cells. Anoikis sensitizing effect on normal small airway epithelial cells was not observed indicating the specificity of D6-MA and digitoxin for NSCLC. These results identify a novel cardiac glycoside (CG) sensitizing anoikis mechanism and provide a promising anti-metastatic target for lung cancer therapy.
77	HM	anoikis	inhibitor	32366403	HM treatment significantly inhibited growth and survival of detached lung cancer cells as indicated by the reduced colony number and size of anchorage-independent growth analysis. HM inhibited cell migration and suppressed filopodia formation. Protein analysis indicated that the compound dramatically decreased integrin β3 and its related downstream proteins including active focal adhesion kinase (FAK) and active protein kinase B (AKT); however, integrin β1 and α5 were found to be unaltered.
78	α-Lipoic acid	anoikis	inducer	27431988	Chemotherapeutic failure and metastasis are the main causes of high mortality rate in lung cancer. Alteration of cellular redox status in response to endogenous stimuli or exogenous compounds has a significant impact on cell signaling and behavior. Herein we divulge for the first time that lung cancer cells exposed to α-lipoic acid (LA) resulted in a higher level of cellular superoxide anion (O2·-) and hydrogen peroxide (H2O2), and such an increase of the specific reactive oxygen species (ROS) downregulated integrin β1 and β3, the integrins known for potentiating aggressive behavior and metastasis. The LA-treated cells exhibited significant decrease in their abilities to survive in detached condition and grow in anchorage-independent soft agar assay. Furthermore, LA sensitized the cells to cisplatin, etoposide and paclitaxel-induced apoptosis. For underlying mechanism, we found that the treatment of the cells with LA significantly decreased integrin β1 and β3, while had no effect on integrin α5 and αv. Interestingly, survival protein p-AKT and anti-apoptotic protein Bcl-2 were reduced in an association to such integrin modulations. Using ROS probes and selective anti-oxidants, we have shown that H2O2 and O2·- induced by LA are key players for the decrease of β1 and β3 integrins, respectively. These findings indicate a novel effect of LA as well as specific ROS, O2·- and H2O2 in integrin regulation, anoikis and chemotherapeutic sensitizations. 
79	Zinc	anoikis	inducer	26928126	Anoikis is a particular type of apoptosis induced by the loss of cell attachment from extracellular matrix. It has been shown to play a critical role in the inhibition of cancer metastasis. Herein, we report for the first time that zinc, an essential trace element, has anoikis sensitizing activity against lung cancer cells. An anoikis assay showed that zinc treatment at the concentrations of 0-50 µM enhanced the anoikis response in human lung cancer H460 cells with significant decreased cell viability and increased number of apoptosis cells detected with Hoechst 33342 and PI co-staining assay. Moreover, zinc significantly inhibited the growth of cancer cells in an anchorage-independent condition. This is mediated through the zinc-induced decrease in prosurvival active protein kinase B (Akt) and metastasis-regulating caveolin-1 (Cav-1) protein expression. Taken together, our results indicate that zinc sensitizes non-small cell lung cancer cells to anoikis and may play a role in the prevention of cancer metastasis.
80	Anti-GD2 ganglioside mAbs	anoikis	inducer	15923178	Anti-GD2 ganglioside antibodies could be a promising, novel therapeutic approach to the eradication of human small cell lung cancers, as anti-GD2 monoclonal antibodies (mAbs) induced apoptosis of small cell lung cancer cells in culture. In this study, we analyzed the mechanisms for the apoptosis of these cells by anti-GD2 mAbs and elucidated the mechanisms by which apoptosis signals were transduced via reduction in the phosphorylation levels of focal adhesion kinase (FAK) and the activation of a MAPK family member, p38, upon the antibody binding. Knock down of FAK resulted in apoptosis and p38 activation. The inhibition of p38 activity blocked antibody-induced apoptosis, indicating that p38 is involved in this process. Immunoprecipitation-immunoblotting analysis of immune precipitates with anti-FAK or anti-integrin antibodies using an anti-GD2 mAb revealed that GD2 could be precipitated with integrin and/or FAK. These results suggested that GD2, integrin, and FAK form a huge molecular complex across the plasma membrane. Taken together with the fact that GD2+ cells showed marked detachment from the plate during apoptosis, GD2+ small cell lung cancer cells seemed to undergo anoikis through the conformational changes of integrin molecules and subsequent FAK dephosphorylation.
81	Anti-LN-332 mAbs	anoikis	inhibitor	19582877	LN-332 mAbs reduce anoikis resistance and migration, associated with tumor cell–matrix interaction.
82	CEACAM6 mAbs	anoikis	inducer	19582877	Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) plays a crucial role in tumorigenesis of lung cancer. However, the therapeutic potential for anti CEACAM6 monoclonal antibody (mAb) has only been limitedly explored. Here, we evaluate the therapeutic potential of naked anti CEACAM6 mAb against lung adenocarcinoma. Clone 8F5, recognizing B domain of CEACAM6, is established by immunizing A549 cells and screening for clones double positive for A549 and CEACAM6-Fc recombinant protein. We found that 85.7% of 70 resected lung adenocarcinoma tissue sections were positive for CEACAM6, whereas all squamous cell carcinoma examined were negative. A549 cells with high levels of CEACAM6 demonstrated more aggressive growth nature and showed increased paclitaxel chemosensitivity upon 8F5 binding. Treatment with 8F5 to A549 decreased cellular CEACAM6 expression and reversed anoikis resistance. 8F5 also decreased cellular status of Akt phosphorylation and increased apoptosis via caspase activation. In a mouse model of lung adenocarcinoma with xenotransplanted A549 cells, 8F5 treatment alone demonstrated 40% tumor growth inhibition. When combined with paclitaxel treatment, 8F5 markedly enhanced tumor growth inhibition, up to 80%. In summary, we demonstrate that anti CEACAM6 mAb is an effective therapeutic treatment for lung adenocarcinoma whose effect is further enhanced by combined treatment with paclitaxel.
83	Cilengitide	anoikis	inducer	24014381	Toxicity was infrequent and mild, with the exception of one episode of grade 2 pain possibly related to cilengitide. Two intratumoral hemorrhages were reported, but only one (grade 2) was deemed to be possibly related to cilengitide and was in the context of disease progression. One patient with GBM received cilengitide for 20 months and remains alive with continuous stable disease. There were no other responders, with median time to tumor progression of 28 days (range, 11-114 days). Twenty-one of the 24 evaluable patients died, with a median time from enrollment to death of 172 days (range, 28-325 days). The 3 patients alive at the time of this report had a follow-up time of 37, 223, and 1068 days, respectively.
84	Gefitinib	anoikis	inducer	14638850	Although no objective tumor responses were seen among the 53 assessable patients, only 21% of patients (11 of 53 patients) had measurable disease at treatment initiation. Seventeen percent of patients (nine of 53 patients) underwent at least six 4-week cycles, and the 6-month event-free survival (EFS) was 13% (seven of 53 patients). The median EFS time was 8.1 weeks, and the median overall survival (OS) time from treatment initiation was 39.4 weeks. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Drug-related toxicities were more frequent at higher doses. Withdrawal caused by drug-related adverse events occurred in 6% of patients (three of 53 patients). Although the presence of diarrhea positively predicted favorable OS from treatment initiation, epidermal growth factor receptor expression did not correlate with either EFS or OS.
85	Erlotinib	anoikis	inducer	33963476	Between November 2011 and March 2018, nine patients with disease progression after initial radiotherapy were enrolled. Median PFS at start of the study was 7.3 months (range 3.5-10.0). In the first dose cohort, one patient experienced a DLT (grade III acute diarrhea), resulting in enrollment of three additional patients in this cohort. No additional DLTs were observed in consecutive patients receiving up to a maximum dose of 85 mg/m2. Median sPFS was 3.2 months (range 1.0-10.9), and median OS was 13.8 months (range 9.3-33.0). Overall QoL was stable during treatment.Daily erlotinib is safe and well tolerated in doses up to 85 mg/m2 when combined with biweekly bevacizumab and irinotecan in children with progressive DIPG. Median OS of the study patients was longer than known form literature.
86	OSI-906	anoikis	inducer	26561558	Insulin and IGF1 induced significant protection against gefitinib in the majority of EGFR-dependent PDX lines with one exception that did not express InsR or IGF1R. Blockade of the InsR/IGF1R pathway synergistically improved sensitivity to gefitinib or dacomitinib. Gefitinib alone effectively attenuated EGFR activities and the downstream MEK/ERK pathway. However, repression of AKT and induction of apoptosis required concurrent inhibition of both EGFR and InsR/IGF1R. A combination of gefitinib and OSI-906, a dual InsR/IGF1R inhibitor, was more effective than either agent alone to treat subcutaneous glioblastoma xenograft tumors.
87	Larotrectinib	anoikis	inducer	34850167	As of July 2020, 33 patients with TRK fusion-positive CNS tumors were identified (median age: 8.9 years; range: 1.3-79.0). The most common histologies were high-grade glioma (HGG; n = 19) and low-grade glioma (LGG; n = 8). ORR was 30% (95% confidence interval [CI]: 16-49) for all patients. The 24-week disease control rate was 73% (95% CI: 54-87). Twenty-three of 28 patients (82%) with measurable disease had tumor shrinkage. The 12-month rates for duration of response, progression-free survival, and overall survival were 75% (95% CI: 45-100), 56% (95% CI: 38-74), and 85% (95% CI: 71-99), respectively. Median time to response was 1.9 months (range 1.0-3.8 months). Duration of treatment ranged from 1.2-31.3+ months. Treatment-related adverse events were reported for 20 patients, with grade 3-4 in 3 patients. No new safety signals were identified. In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile.
88	Trabedersen	anoikis	inducer	20980335	This randomized, open-label, active-controlled, dose-finding phase IIb study evaluated the efficacy and safety of trabedersen (AP 12009) administered intratumorally by convection-enhanced delivery compared with standard chemotherapy in patients with recurrent/refractory high-grade glioma. One hundred and forty-five patients with central reference histopathology of recurrent/refractory glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) were randomly assigned to receive trabedersen at doses of 10 or 80 µM or standard chemotherapy (temozolomide or procarbazine/lomustine/vincristine). Primary endpoint was 6-month tumor control rate, and secondary endpoints included response at further timepoints, survival, and safety. Six-month tumor control rates were not significantly different in the entire study population (AA and GBM). Prespecified AA subgroup analysis showed a significant benefit regarding the 14-month tumor control rate for 10 µM trabedersen vs chemotherapy (p= .0032). The 2-year survival rate had a trend for superiority for 10 µM trabedersen vs chemotherapy (p = .10). Median survival for 10 µM trabedersen was 39.1 months compared with 35.2 months for 80 µM trabedersen and 21.7 months for chemotherapy (not significant). In GBM patients, response and survival results were comparable among the 3 arms. Exploratory analysis on GBM patients aged ≤55 years with Karnofsky performance status >80% at baseline indicated a 3-fold survival at 2 and 3 years for 10 µM trabedersen vs chemotherapy. The frequency of patients with related or possibly drug-related adverse events was higher with standard chemotherapy (64%) than with 80 µM trabedersen (43%) and 10 µM trabedersen (27%). Superior efficacy and safety for 10 µM trabedersen over 80 µM trabedersen and chemotherapy and positive risk-benefit assessment suggest it as the optimal dose for further clinical development in high-grade glioma.
89	Cediranib	anoikis	inducer	34715143	Cediranib reduced GB cell proliferation, induced apoptotic cell death and inhibited the aggressive abilities of GB cells. Cediranib synergistically increased the anti-proliferative and apoptotic effects of radiotherapy and bevacizumab and augmented the sensitivity of GB cells to temozolomide chemotherapy. In addition, knockdown of MET and AKT potentiated cediranib sensitivity in cediranib-resistant GB cells.
90	DSF	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
91	AEB071	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
92	nanoencapsulated doxorubicin	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
93	berberine	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
94	salinomycin	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
95	PEM POL5551	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
96	AL10	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
97	5-azacytidine	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
98	synthesized flavonoid derivative GL-V9	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
99	Tubeimoside V	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.
100	HPW-RX40	anoikis	inhibitor	31154235	It is therefore important to understand the anoikis-related molecular pathways in order to design effective therapies for TNBC. Several compounds have been shown to possess the potential to regulate anoikis in breast cancer cells such as DSF, AEB071, nanoencapsulated doxorubicin, berberine, salinomycin, PEM POL5551, AL10, 5-azacytidine, synthesized flavonoid derivative GL-V9, Tubeimoside V (TBMS-V) and HPW-RX40. We reviewed the molecular basis of anoikis regulation, its potential role as an important target to inhibit metastasis in TNBC, and potential anoikis modulators that could serve as drug candidates.